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1 Summary 
DCs control T cell tolerance and immunity in peripheral lymphoid organs. A critical 
hallmark of DC biology is their capacity to change their maturation status in response 
to inflammatory signals. Current immunological concepts suggest that the decision to 
tolerize T cells or to induce T cell immunity directly depends on the maturation status 
of DCs. However, it has been suggested that mature DCs have both, tolerogenic and 
immunogenic potential. To test this model, we sought to generate transgenic mice in 
which DCs receive a chronic stimulation signal and are induced to become mature, 
but not immunogenic. To this end, we designed a transgenic mouse model with a DC-
specific expression of the fusion protein LMP1/CD40, which mimics chronic CD40 
stimulation. We used this model to study how DC maturation influences tolerance 
induction in vivo. 
The resulting DC-LMP1/CD40 mice developed colitis, wasting disease, 
splenomegaly, increased levels of serum pro-inflammatory cytokines and increased 
levels of serum IgA and IgM. Fully matured DCs were detected in the intestines but 
not in the spleens of these mice, suggesting that additional triggers in the gut may lead 
to complete maturation of the DCs and be the cause of intestinal pathology. However, 
tolerance was induced in transfer experiments where CD8 T cells were administered 
systemically.  
We therefore conclude that the constitutive CD40 signal lowers the activation 
threshold of DCs. This signal is itself not sufficient to induce autoimmunity in most 
organs and tissues, but additional stimuli probably by microbes at border-surfaces of 
the body, such as gut and skin, strongly activate DCs and trigger inflammatory 
autoreactive immune responses. The work presented in this thesis indicates that CD40 
crosslinking is an important mediator to amplify activation signals towards T cells in 
vivo, but that this is only the case when microbial stimuli are additionally present. 
These findings demonstrate that DC maturation needs tight and organ-specific 
regulation in order to avoid autoimmune disorders. 
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2 Zusammenfassung 
Dendritische Zellen (dendritic cells, DCs) regulieren T-Zell-Toleranz und -Immunität 
in den peripheren Lymphorganen. Ein besonderes Kennzeichen der DC-Biologie ist 
die Fähigkeit, ihren Reifezustand als Antwort auf Entzündungssignale zu ändern. 
Aktuelle immunologische Konzepte weisen darauf hin, dass die Entscheidung T-Zell-
Toleranz oder T-Zell-Immunität zu induzieren direkt mit dem Reifezustand der DCs 
zusammenhängt. Trotzdem wird vermutet, dass reife DCs sowohl tolerogenes als auch 
immunogenes Potential haben können. Um dieses Modell zu testen, wollten wir eine 
transgene Maus entwickeln, in der DCs ein dauerhaftes Stimulationssignal erhalten 
und angeregt werden, reif aber nicht immunogen zu werden. Zu diesem Zweck haben 
wir ein transgenes Mausmodell mit einer DC-spezifischen Expression des 
Fusionsproteins LMP1/CD40 entworfen, das chronische CD40-Stimulation imitiert. 
Wir haben dieses Modell verwendet, um herauszufinden, wie die Reifung von DCs 
die Toleranzinduktion in vivo beeinflusst. 
Die transgene DC-LMP1/CD40-Maus entwickelte eine Dickdarmentzündung, das 
Wasting-Syndrom und Splenomegalie, außerdem waren erhöhte Level von 
inflammatorischen Zytokinen sowie von IgA und IgM im Serum messbar. Voll 
ausgereifte DCs wurden im Darm dieser Mäuse entdeckt, jedoch nicht in der Milz. 
Dies deutet darauf hin, dass zusätzliche Stimuli im Darm zur vollständigen Reifung 
der DCs führen und somit der Grund für die Pathologie des Darms sein können. 
Dennoch wurde in Transferexperimenten, in denen CD8 T-Zellen systemisch 
appliziert wurden, Toleranz induziert. 
Deshalb kommen wir zu dem Schluss, dass das konstitutive CD40-Signal die 
Aktivierungsschwelle von DCs erniedrigt. Dieses Signal als solches reicht aber in den 
meisten Organen und Geweben nicht aus um Autoimmunität zu induzieren. 
Allerdings können zusätzliche Stimuli, wahrscheinlich Mikroorganismen, an den 
Körpergrenzen wie im Darm und in der Haut DCs aktivieren und autoreaktive 
Immunantworten hervorrufen. Die Arbeit, die in dieser Dissertation präsentiert wird, 
zeigt, dass die CD40-Vernetzung ein wichtiger Mediator ist, um die an T-Zellen 
gerichtete Aktivierungssignale in vivo zu vergrößern. Allerdings ist dies nur der Fall, 
wenn zusätzlich mikrobielle Stimuli vorhanden sind. 
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Diese Erkenntnisse zeigen, dass die strikte und Organ-spezifische Regulierung der 
DC-Reifung äußerst wichtig ist um autoimmune Funktionsstörungen zu vermeiden. 
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3 Introduction 
3.1 The immune system 
All multicellular organisms possess an immune system to defend themselves from 
pathogens such as viruses, bacteria, or parasites. The vertebrate immune system can 
be divided into two main arms: the innate and the adaptive system. The innate 
immune system consists of physical and chemical barriers, such as skin, gastric acid, 
mucus or tears as well as cells, such as phagocytes and natural killer cells, and 
physiological systems, such as complement. The innate immune system has limited 
specificity but provides a quick first defense after infection and plays a key role in 
stimulating adaptive immune responses. 
The adaptive immune system is composed of specific antibody production by B cells 
(humoral immunity) and antigen-specific T-cell activity (cell-mediated immunity). 
Common lymphoid progenitor cells develop in the bone marrow and migrate to the 
thymus where they mature into T-cells. They express an antigen-binding receptor, the 
T-cell receptor, on their surface. The T-cell receptor recognizes only antigen that is 
bound in peptide form to major histocompatibility complex (MHC) molecules, cell-
membrane proteins expressed on antigen-presenting cells (APCs). 
B cells develop in the bone marrow and migrate to the spleen for their final 
maturation. They act as APCs and produce highly specific antibodies against antigens. 
 
3.2 Dendritic cells 
The most effective APCs are the dendritic cells (DCs). DCs were first described by 
Steinman and Cohn in 1973 (Steinman and Cohn, 1973). Their high efficiency as 
APC is partly due to their constitutive expression of MHC class II (MHC-II) 
molecules and ability to express a number of costimulatory molecules, such as 
CD80/86 and CD40. Their positioning in vivo, namely tissues in contact with the 
external environment, allows them to capture antigens before migrating to lymphoid 
tissues, where they can induce potent T-cell clonal expansion and effector function. 
The ability of DCs to regulate immunity is dependent on DC maturation. A variety of 
factors can induce maturation following antigen uptake and processing within DCs, 
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including whole bacteria or bacterial-derived antigens, inflammatory cytokines, 
ligation of specific cell surface receptors, and viral products. Immature DCs are 
recruited to sites of inflammation in peripheral tissues following pathogen invasion. 
After internalization of foreign antigens and processing, DCs migrate to T-cell-rich 
areas within lymphoid organs via blood or lymph, present the antigen and induce 
immune responses. 
 
3.2.1 DC development 
DC differentiation is dependent on a combination of cytokines and transcription 
factors. DCs develop from bone marrow derived hematopoietic stem cells. These 
differentiate into a common myeloid progenitor (CMP) that gives rise to DCs, 
monocytes, macrophages, granulocytes, megakaryocytes and erythrocytes (Liu and 
Nussenzweig, 2010). CMPs differentiate into granulocytes/macrophage progenitors 
(GMP), which give rise to macrophage-dendritic cell progenitors (MDP). MDPs have 
the potential to differentiate into common DC precursors (CDP) or monocytes (Fig. 3-
1). CDPs can give rise to either plasmacytoid DCs (pDCs) or the direct precursors of 
most of the DC subsets that are discussed in detail in the next chapter. The 
transcription factors Batf3, IRF8 and Id2 play an important role in the final 
differentiation to CD8+ lymphoid tissue DCs, whereas the transcription factors RelB, 
IRF2, IRF4 and RBP-J are important for the differentiation to CD8- lymphoid tissue 
DCs. The development of non-lymphoid tissue DCs is predominantly dependent on 
Flt3 and M-CSF recognition. 
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Figure 3-1: Origin of Batf3-IRF8-Id2-dependent and -independent tissue-resident DCs in mice. 
This figure illustrates the precursors, transcription factors (black), and cytokine receptors (red) 
required for the development of each population. Adapted from (Hashimoto et al., 2011). 
 
3.2.2 DC subsets 
There are several ways to distinguish the different DC subsets (Steinman and Idoyaga, 
2010). One is to differentiate between monocyte-independent DCs, which require Flt-
3L for their development and are mostly found in lymphoid tissue, and monocyte-
derived DCs, which are dependent on M-CSF (Schmid et al., 2010). Other 
nomenclatures distinguish conventional or classical DCs from plasmacytoid DCs, 
which do not originate from the same precursor, or resident from migratory DCs. 
Here, I focus on the differences between lymphoid and non-lymphoid tissue DCs. 
However, lymphoid and non-lymphoid tissues can contain similar DC subsets 
(Steinman and Idoyaga, 2010). 
 
3.2.2.1 Lymphoid tissue DC 
Lymphoid tissue DCs reside in the spleen, lymph nodes, thymus and mucosal 
associated tissues. DCs are classified into two main subsets, namely the classical and 
the plasmacytoid DCs. The classical DC (cDC) subset consists of CD8+ and CD8- 
DCs (Naik, 2008). CD8+ DCs are mainly found in the T cell areas of the spleen and 
lymph nodes in the steady state and are specialized for the uptake of dying cells and 
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the presentation of endogenous antigens, such as viral antigens. In addition to 
presentation via MHC-II, CD8+ DCs are also capable of crosspresentation of 
exogenous antigens via the MHC class I (MHC-I) pathway to CD8+ T cells (den 
Haan et al., 2000). In contrast to their CD8+ counterparts, CD8- DCs localize 
predominantly in the marginal zone (Leenen et al., 1998). They are specialized in 
presenting exogenous antigens via MHC-II (Dudziak et al., 2007). The lymph nodes 
also contain migratory DCs. These cells derive from the periphery where they act as 
sentinels for pathogen and peripheral self-antigen. Then they migrate towards 
draining lymph nodes accompanied by a kind of maturation (Naik, 2008). These 
migratory DCs include Langerhans cells and dermal DCs that drain to the skin-
draining lymph nodes (Merad and Manz, 2009). 
Plasmacytoid DCs, also called natural interferon-producing cells, accumulate mainly 
in the lymphoid organs and express TLR7 and TLR9, which recognize single stranded 
RNA and unmethylated CpG sequences, respectively. pDCs are therefore good 
responders to viral antigens and produce large amounts of type I interferons (IFN) 
upon exposure to live and inactivated virus. However, the role of pDCs in vivo is still 
matter of debate, as in pDC-depleted mice it was shown that, pDCs provide an 
immediate but limited source of type I IFN that restricts viral burden only in the very 
early phase of infection (Swiecki et al., 2010). In other studies, it was demonstrated 
that pDC-knockout mice live into old age without obvious signs of autoimmunity or 
inflammation, suggesting that pDCs are not important mediators of tolerance (Cisse et 
al., 2008; Reizis et al., 2011). 
Thymic DCs are mostly found in the thymic medulla and play an important role in the 
negative selection of thymocytes (Brocker et al., 1997). Here, the CD8+ DCs seem to 
derive from an early thymocyte progenitor while the thymic CD8- Sirp-α+ DCs are 
thought to have an extra-thymic origin (Wu and Shortman, 2005) and home to the 
thymus. It has been speculated that these migratory thymic DCs carry antigen to the 
thymus contributing to the establishment and maintenance of central tolerance 
(Bonasio et al., 2006).  
The mucosal-associated tissues comprise lymphoid tissue in the nasopharynx, Peyers 
patches and isolated lymphoid follicles in the small intestine, and isolated follicles 
and the appendix in the large intestine. The DCs found in these tissues resemble 
splenic DC (Iwasaki, 2007). 
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3.2.2.2 Non-lymphoid tissue DC 
Non-lymphoid tissue DCs can be found in the skin, lung, liver, kidney, pancreatic 
islets and the intestine (Fig. 3-2). They populate stratified squamous tissue like the 
epidermis or connective tissue. These cells are called interstitial DCs (Helft et al., 
2010). 
 
Figure 3-2: Characterization of tissue-resident DCs. 
Two DC compartments with distinct cell surface phenotype and immune function have been 
identified in most non-lymphoid tissues. The nature of the bone marrow precursor that gives rise 
to each DC subset, the growth factor receptor requirements, and the transcription factors that 
control their development are summarized here. Additional DC populations can be found in the 
skin and intestine. In the skin, embryonically derived DCs also called Langerhans cells, populate 
the epidermis. In the intestine, a population of CD103+ DCs with a phenotype and regulatory 
program that is distinct to that of most non-lymphoid tissue CD103+ DCs populates the lamina 
propria, Adapted from (Helft et al., 2010). 
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Both types are found in the skin. Langerhans cells are M-CSF dependent (Ginhoux et 
al., 2006) and are found within the epidermis and other stratified squamous tissue, 
while dermal DCs belong to the interstitial DC subset (Merad et al., 2008). 
DCs in the lung parenchyma resemble interstitial cutaneous DCs, as there are two 
main populations, the CD103+ and the CD11b+ DCs (Sung et al., 2006). 
Liver, kidney and pancreatic islet DCs express similar markers to dermal and lung 
DCs, including CD103 and CD11b (Ginhoux et al., 2009). 
Intestinal DCs accumulate mainly in the intestinal lymphoid tissue, such as Peyer’s 
patches, lymphoid follicles and the mesenteric lymph nodes. However, they are also 
found in the lamina propria, the muscular layers and the serosa. Dendritic cells in gut-
associated tissue must have a highly tolerogenic phenotype as they come into contact 
with a large number of commensal bacteria and food antigens. However, these cells 
are also able to fight enteric pathogens. CD103+ DCs promote the differentiation of T 
regulatory (Treg) cells via a mechanism that involves retinoic acid (RA) and TGF-β 
(Coombes et al., 2007; Sun et al., 2007), and CD103- DCs can drive the 
differentiation of TH17 and TH1 cells (Coombes and Powrie, 2008). In the following 
section I will further describe the several DC subsets in the lamina propria DCs 
(Hashimoto et al., 2011). 
CD103- CD11b+ DCs arise from circulating monocyte precursors and are M-CSF 
dependent (Bogunovic et al., 2009; Schulz et al., 2009; Varol et al., 2009). They are 
poor T cell stimulators (Schulz et al., 2009) and do not migrate effectively to the 
draining lymph nodes during oral infection (Bogunovic et al., 2009; Ginhoux et al., 
2009; Varol et al., 2009). 
The development of CD103+ CD11b+ DCs depends on Flt3L and GM-CSF and they 
derive from DC-restricted precursors (Bogunovic et al., 2009; Varol et al., 2009). 
Contrary to CD103- CD11b+ DCs, CD103+ CD11b+ DCs migrate to the draining 
lymph node upon oral microbial stimuli (Bogunovic et al., 2009; Schulz et al., 2009). 
A third subset of DCs is found in the lamina propria. These CD103+ CD11b- DCs 
also originate from DC-restricted precursors and depend on the same transcription 
factors as lymphoid tissue CD8+ DCs, including Batf3 (Hildner et al., 2008), IRF8 
(Aliberti et al., 2003; Schiavoni et al., 2002; Tailor et al., 2008) and the inhibitor of 
DNA protein Id2 (Hacker et al., 2003) (Fig. 3-1). CD8+ and CD103+ CD11b- DC 
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subsets also share common functions, as they can express high amounts of IL-12, 
cross-present antigens to CD8+ T cells and drive the differentiation of CD8+ effector 
T cells (Hashimoto et al., 2011). 
 
3.2.3 DC maturation 
In response to environmental stimuli, immature DCs start a process called maturation, 
during which they undergo multiple phenotypical and functional changes. The process 
of DC maturation involves a redistribution of MHC molecules from intracellular 
endocytic compartments to the DC surface, down-regulation of antigen 
internalization, an increase in the surface expression of costimulatory molecules, 
morphological changes, cytoskeleton reorganisation, secretion of chemokines, 
cytokines and proteases, and surface expression of adhesion molecules and 
chemokine receptors (Steinman and Idoyaga, 2010). 
 
3.2.4 Induction of Immunity by DC 
DCs possess the ability to stimulate naïve T cells. Because of their ability to strongly 
up-regulate costimulatory molecules, they are more potent T cell stimulators than B 
cells and macrophages (Steinman and Witmer, 1978). When DCs mature, the T cells 
not only get the antigen-specific signal 1 that is mediated through the T cell receptor 
(TCR), but also are stimulated via CD28 (signal 2) because of the up-regulation of B7 
molecules on DCs (Kapsenberg, 2003). This process leads to T cell proliferation. 
After having received signal 2, CD4+ T cells up-regulate their expression of CD40L, 
which binds to CD40 receptors on the DCs, stimulating the DCs to produce cytokines 
(signal 3). Depending on the type of pathogen-associated molecular pattern (PAMP) 
that was recognized by the DC, appropriate cytokines are produced for the induction 
of specific types of T helper (TH) cells, in a process known as T helper polarization. 
There are three main TH cell subtypes, which differ in their cytokine profiles and their 
functions in the immune response. TH1 cells mainly secrete the pro-inflammatory 
cytokine IFN-γ and are responsible for killing intracellular pathogens and for 
perpetuating autoimmune responses. TH2 cells produce IL-4, -5 and -13, which are 
associated with the promotion of IgE production and eosinophilic responses, and 
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therefore play an important role in fighting extracellular pathogens and allergies. A 
third subset of TH cells, the TH17 cells, are potent inflammatory mediators and 
contribute to several autoimmune disorders, such as asthma, rheumatoid arthritis and 
inflammatory bowel disease (IBD). They are also important for immune responses 
against fungi and extracellular bacteria. TH17 cells secrete the cytokines IL-17A and 
IL-17F, which activate and recruit neutrophils, IL-21, which activates the TH17 cells 
in an autologous manner and activates B cells, and IL-22, which has pro-
inflammatory and tissue-protective functions (Hemdan et al., 2010). 
The priming of CD8+ T cells must be tightly regulated, as cytotoxic T lymphocytes 
(CTL) can induce potent immune responses and therefore, if not controlled, could 
cause severe autoimmunity. To avoid this, CD8+ T cells lack CD40L, rendering them 
incapable of directly stimulating DCs. Thus, they are dependent on help provided by 
CD4+ TH cells that recognize the same antigen on the DC and ‘license’ it via CD40 in 
order to prime CD8+ T cells (Smith et al., 2004). 
 
3.2.5 DC in tolerance induction 
An important feature of the immune system is the capacity for recognizing and 
fighting foreign antigens, while remaining tolerant to self-antigens. If this process 
becomes imbalanced and self-antigen is recognized as foreign, autoimmune diseases 
may result. There are at least two important mechanisms that are responsible for 
tolerance maintenance: central and peripheral tolerance, during which deletion, 
anergy or induction of Treg cells occurs. 
 
3.2.5.1 Central tolerance 
The induction of central tolerance takes place in the primary lymphoid organs. B cells 
are selected in the bone marrow and T cells in the thymus, where autoreactive clones 
are negatively selected and undergo apoptosis. DCs play a pivotal role during this 
process. It has been shown that targeted expression of MHC-II molecules on thymic 
DCs, but not on cortical or medullary epithelial cells, B cells or macrophages, is 
sufficient to negatively select I-E reactive CD4+ T cells, and to a less complete extent, 
CD8+ T cells (Brocker et al., 1997). Furthermore, it has been demonstrated that CD8lo 
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Sirp-α+ DCs in the thymus efficiently induce the generation of Treg cells and 
negative selection (Proietto et al., 2008). The important role of DCs in maintaining 
central tolerance was underscored by a study showing that constitutive ablation of 
DCs in mice breaks self-tolerance of CD4+ T cells and results in spontaneous fatal 
autoimmunity (Ohnmacht et al., 2009). 
 
3.2.5.2 Peripheral tolerance 
Although negative selection in the thymus is a highly effective mechanism, some 
autoreactive T cells still escape to the periphery. It is therefore important that 
peripheral tolerance mechanisms exist that can inactivate these T cells. DCs play an 
important role in maintaining peripheral tolerance, as they are capable of inducing 
deletion, anergy and the induction of Treg cells. In the steady state, DC pick up dead 
cells, process them and present them in the context of MHC to T cells, which are 
thereby inactivated (Steinman et al., 2000). It has been shown that a DC-specific 
deficiency in uptake of apoptotic material inhibits crosspresentation in vivo leading to 
an accumulation of self-reactive T cells in the periphery (Luckashenak et al., 2008). 
DCs must be immature during the presentation of self-antigen as autoimmunity would 
arise if they were entirely immunocompetent (Reis e Sousa, 2006). This reasoning led 
to the general understanding that immature DCs induce tolerance and mature DCs 
induce immunity. But this paradigm of immature vs. mature DC is currently under 
debate (Joffre et al., 2009; Lutz and Schuler, 2002; Reis e Sousa, 2006). Our group 
and others have shown that tolerogenic DC express substantial amounts of 
costimulatory molecules (Albert et al., 2001; Kleindienst et al., 2005; Menges et al., 
2002), that the expression of costimulatory molecules is necessary for tolerance 
induction (Perez et al., 1997; Probst et al., 2005) and that immature DC are ignored by 
T cells (Albert et al., 2001). 
 
3.3 The CD40 receptor 
CD40, a member of the tumor necrosis factor (TNF) receptor superfamily, is a 48 kDa 
transmembrane glycoprotein receptor that was first discovered on B lymphocytes but 
is also expressed by dendritic cells, monocytes, activated macrophages, endothelial, 
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epithelial cells and some tumor cells. The murine CD40 receptor consists of 305 
amino acids (AA) with an extracellular domain of 193 AA containing the 
characteristic four cysteine-rich repetitive motives of the TNF-receptor family. In 
addition, the receptor contains a leader sequence of 21 AA, a transmembrane domain 
of 22 AA and an intracellular signaling domain with a length of 90 AA. 
The signaling cascade downstream of CD40 is initiated once the trimeric ligand 
CD40L is bound to the receptor. CD40L is primarily expressed on activated CD4+ T 
cells, but has also been found on platelets, mast cells, DCs, macrophages, basophils, 
eosinophils, NK cells and B cells, as well as non-haematopoietic cells (smooth muscle 
cells, endothelial cells, and epithelial cells) (Schonbeck and Libby, 2001). 
The signaling domain of CD40 receptor lacks intrinsic catalytic activity, but contains 
two PxQxT-motives that bind to TNF receptor associated factor (TRAF) 1, 2, 3, 5 and 
6 upon CD40L binding (Harnett, 2004). TRAF binding to the cytoplasmic tail of 
CD40 subsequently leads to the activation of the canonical and non-canonical nuclear 
factor-κB (NF-κB) pathways (Berberich et al., 1994; Coope et al., 2002) and the 
mitogen activated protein kinases (MAPKs) extracellular signal regulated kinase 
(Erk), c-Jun N-terminal kinase (Jnk) and p38 (Harnett, 2004; van Kooten and 
Banchereau, 2000). 
The AA-sequence of the human CD40 receptor is 62% identical to that of the murine 
receptor. They share 78% identity in the intracellular domains. The last 32 
carboxylterminal AA of the human CD40 are completely conserved in the mouse 
sequence. Furthermore, it had been shown that the human CD40 can rescue the 
phenotype of CD40-deficient mice (Yasui et al., 2002), suggesting that the findings of 
studies performed in one species are likely to also be applicable to the other (van 
Kooten and Banchereau, 2000). 
 
3.3.1 CD40 on dendritic cells 
Following the discovery of CD40 on DCs (Freudenthal and Steinman, 1990; Romani 
et al., 1989), it was also shown that CD40 signaling induces the maintenance of high 
levels of MHC-II and up-regulation of costimulatory molecules such CD80 and CD86 
(Caux et al., 1994; Pinchuk et al., 1994; Sallusto and Lanzavecchia, 1994). Therefore, 
DCs become more effective APCs after CD40 crosslinking, a process which had 
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already been shown for B cells (Clark and Ledbetter, 1994). However, DCs and B 
cells respond differently to CD40 stimulation, with DCs producing higher levels of 
certain inflammatory cytokines and chemokines (Cella et al., 1996; Kiener et al., 
1995). 
Several studies show that DCs acquire immunostimulatory capacities, such as the 
secretion of pro-inflammatory cytokines like IL-12, upon CD40 ligation in vitro 
(Cella et al., 1996) as well as in vivo during immunizations (Bonifaz et al., 2002; 
Hawiger et al., 2001; Liu et al., 2002). However, there are several limitations to these 
systems. In vitro, the DCs are also stimulated by growth factors, serum and plastic, 
which can have synergistic effects with CD40 ligation. The in vivo-stimulations were 
performed by the injection of an agonistic anti-CD40 antibody that has been shown to 
induce a B cell-dependent inflammatory liver disease (Kimura et al., 2006), not 
excluding indirect and DC-unspecific effects. Furthermore, the outcome of such 
experiments is dependent on the purity of the antibody, which could be contaminated 
by other inflammatory stimuli. 
Other groups have shown that CD40-signaling induces incomplete DC maturation in 
vivo (Ahonen et al., 2004; Sanchez et al., 2007; Schulz et al., 2000). In these studies, 
only combined CD40/TLR signals completely matured DCs, including IL-12 and type 
I IFN secretion and CD70 up-regulation. 
As the anti-CD40 antibody is not a good choice for in vivo studies because of the side 
effects it possibly causes, a modified constitutively active CD40 molecule that can be 
expressed specifically on DCs was considered for the project. 
 
3.4 LMP1 and CD40 
The Epstein-Barr virus belongs to the family of γ-herpes viruses, infects mainly 
human B cells and can establish latency in long-lived memory B cells. During the first 
expansion phase of the virus, called latency phase III, nine viral proteins are 
expressed. These so-called latent proteins are located either in the nucleus, EBV 
nuclear antigen (EBNA)-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C and EBNA-
LP, or in the plasma membrane, latent membrane proteins (LMP)1, LMP2A and 
LMP2B, of the infected cell. In recent years it has been shown that some viral 
proteins bear functional similarities to cellular proteins that are involved in the 
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differentiation, proliferation and survival of B cells. LMP1 imitates an active CD40 
receptor contributing to B cell immortalization and tumor development. LMP1 
consists of 386 AAs containing 186 hydrophobic AAs of the transmembrane domain 
and 200 AAs of the cytoplasmic signaling domain at the carboxyl-terminus. The 
transmembrane domain is composed of six membrane-spanning segments that are 
connected through loops with each other and that mediate aggregation with other 
LMP1 proteins. These aggregations in the plasma membrane act as multimeric 
signaling complexes producing a ligand-independent constitutively active signal. As 
already mentioned, LMP1 resembles CD40 in function (Graham et al., 2010; Lam and 
Sugden, 2003) and both proteins can be partly replaced by each other (Kilger et al., 
1998; Rastelli et al., 2008; Zimber-Strobl et al., 1996). To further compare the two 
molecules, fusion proteins of the transmembrane domain of LMP1 and the 
cytoplasmic domain of CD40 and vice versa were generated. These studies provided 
further evidence that the proteins have similar functions and show equal activation of 
NF-κB (Busch and Bishop, 1999), equal induction of growth factor expression 
(Hatzivassiliou et al., 1998), and equal transformation functions (Hatzivassiliou et al., 
2007) in vitro. In vivo studies also revealed functional similarities (Rastelli et al., 
2008; Uchida, 1999). 
 
3.5 The fusion protein LMP1/CD40 
The fusion protein LMP1/CD40 consists of the transmembrane domain of LMP1 (AA 
1-187) and the intracellular part of the human CD40 receptor (AA 223-280) (Fig. 3-
3). In vitro characterization of the fusion protein demonstrated that LMP1/CD40 acts 
as a constitutive CD40 receptor (Gires et al., 1997). In vivo, it was shown that B cell-
specific expression of LMP1/CD40 led to an activated phenotype, prolonged survival 
and increased proliferation of B cells (Homig-Holzel et al., 2008). Furthermore, 
constitutive CD40 signaling in B cells induced selective and constitutive activation of 
the non-canonical NF-κB pathway and a high incidence of lymphoma development 
between the age of 12 and 19 months. 
Little is known about LMP1/CD40 expression on dendritic cells. In a recent in vitro 
study with human DCs, LMP1 and LMP1/CD40 were introduced into an HIV-1 
construct to produce virions encoding these proteins in order to improve HIV vaccines 
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(Gupta et al., 2011). Transduction of DCs and macrophages with these viruses 
induced up-regulated costimulatory molecules and cytokine production by these cells. 
CD40 crosslinking activates NF-κB. The canonical NF-κB pathway in DCs leads to 
an early production of pro-inflammatory cytokines, whereas it was shown that the 
non-canonical NF-κB pathway leads to the expression of the tolerance-inducing and 
immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO) (Tas et al., 2007). 
As already mentioned, it was demonstrated that LMP1/CD40 in B cells constitutively 
activated the non-canonical NF-κB pathway. If this is also true for DCs, this would be 
another indication that a certain activation level is beneficial for tolerance induction. 
 
 
Figure 3-3: Schematic representation of the LMP1/CD40 fusion protein. 
The fusion protein consists of the transmembrane domain of LMP1 (AA 1-187) and the 
intracellular part of the human CD40 receptor (AA 223-280). Adapted from (Hömig, 2005).
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4 Aims of the thesis 
DCs control T cell tolerance and immunity in peripheral lymphoid organs. A critical 
hallmark of DC biology is their capacity to change their maturation status in response 
to inflammatory signals. Current immunological concepts suggest that the decision to 
tolerize T cells or to induce T cell immunity directly depends on the maturation status 
of DCs. Furthermore, DC maturation needs to be strictly controlled to avoid 
‘spontaneous’ maturation of DCs. However, mature DCs are not necessarily licensed 
DCs that produce signal 3. Therefore, although matured in respect to surface markers, 
mature DCs can possibly induce tolerance (Reis e Sousa, 2006). To test this model, 
we sought to generate transgenic mice in which DCs receive a chronic stimulation 
signal and are induced to become mature, but not licensed. To this end, we designed a 
transgenic mouse model with a DC-specific expression of the fusion protein 
LMP1/CD40, which mimics chronic CD40 stimulation. We used this model to study 
how DC maturation influences tolerance induction in vivo. 
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5 Materials and Methods 
5.1 Materials 
5.1.1 Antibodies 
Specificity (anti-
mouse) 
Conjugate Clone Supplier 
B220 PerCP RA3-6B2 Becton, Dickinson & Co. (BD), 
Franklin Lakes, NJ, USA  
CD3 PerCP 145-2C11 BD  
CD4 PE 
PerCP 
PE-Cy7 
GK1.5 BD  
CD8 PE 
PerCP 
APC-Cy7 
53-6.7 BD  
CD11b PE M1/70 BD 
CD11c APC HL3 BD 
CD19 PerCP 
PE-Cy7 
1D3 BD 
CD25 FITC PC61 BD 
CD44 PE Pgp-1, Ly-24 BD 
Alexa Fluor 
405 
IM7.8.1 Life Technologies, Carlsbad, CA, 
USA  
CD45.1 (Ly5.1) APC 
eFluor 450 
A20 eBioscience, San Diego, CA, 
USA 
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CD45.2 (Ly5.2) APC 104 eBioscience 
CD62L PE Mel-14 BD 
CD70 Biotin FR70 eBioscience 
CD80 PE 16-10A1 BD 
CD86 PerCP GL-1 Biolegend 
CD90.1 FITC 
PerCP 
OX-7 BD 
IL-12 (p40/p70) PE p40/p70 BD 
IL-17A PE TC11-18H10 BD 
IFN-γ PE 
APC 
XMG1.2 BD 
F4/80 PE BM8 BD 
Foxp3 Alexa Fluor 
647 
FJK-16s eBioscience 
MHC-II (I-A/I-E) FITC 
Biotin 
M5/114.15.2 eBioscience 
Ly6C FITC AL-21 BD 
Ly6C/G (Gr-1) FITC RB6-8C5 Biolegend 
NK1.1 PE 
PE-Cy7 
PK136 BD 
Vα2 TCR FITC 
APC 
B20.1 BD 
Vβ5.1/5.2 TCR FITC 
PE 
MR9-4 BD 
 
Table 5-1: Antibodies used in flow cytometry 
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For western blotting, LMP1/CD40 protein was detected by rabbit anti-human CD40 
antibody (sc975) (Santa Cruz Biotechnology). A donkey anti-rabbit HRP-conjugated 
secondary antibody (Jackson Immuno Research) was used. β-actin was detected using 
a rabbit anti-mouse β-actin antibody (13E5) (Cell Signaling Technology). 
Streptavidin-APC was purchased from Life Technologies, Streptavidin-PE from 
Southern Biotec. Streptavidin-PerCP and Streptavidin-APC-Cy7 from BD. 
The agonistic anti-CD40 antibody (clone FGK45.5, isotype rat IgG2a) for 
immunizations was purchased from Miltenyi Biotec. 
5.1.2 Chemicals 
Unless stated otherwise, chemicals were purchased from Merck (Darmstadt, 
Germany), Roth (Karlsruhe, Germany) or Sigma-Aldrich (St. Louis, MO, USA). All 
buffers and solutions were prepared using double distilled water. 
5.1.3 Consumables 
Centricon filter Millipore Corporation, Billerica, MA, USA 
Disposable syringe filter 
(0.2 + 0.45 µm) 
Nalgene Nunc Int., Rochester, NJ, USA 
Bottle filter Nalgene Nunc Int. Rochester, NJ, USA 
Disposable injection needle 
(26 G x 1/2“) 
Terumo Medical Corporation, Tokyo, Japan 
Disposable syringe (1+5 ml) Braun, Melsungen, Germany 
Reaction container 0.2 ml Nunc, Wiesbaden, Germany 
Reaction container 1.5 ml und 2 ml Eppendorf, Hamburg, Germany 
Reaction tube 5 ml BD, Franklin Lakes, NJ, USA 
Reaction tube 15 ml und 50 ml Greiner, Frickenhausen, Germany 
 
Other materials and plasticwares were purchased from BD, Nunc (Wiesbaden, 
Germany) and Greiner. 
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5.1.4 Devices 
Analytic scale (Adventurer, Ohaus Corp., Pine Brooks, NJ, USA), automatic pipettors 
(Integra Biosciences, Baar, Switzerland), bench centrifuge (Centrifuge 5415 D, 
Eppendorf, Hamburg, Germany), cell counter (Coulter Counter Z2, Beckman Coulter, 
Krefeld, Germany), centrifuge (Rotixa RP, Hettich, Tuttlingen, Germany), chemical 
scale (Kern, Albstadt, Germany), flow cytometer (FACSCalibur, FACSCantoII and 
FACSAria, BD), incubator (Hera cell, Heraeus Kendro Laboratory Products, Hanau, 
Germany), laminar airflow cabinet (Heraeus), magnetic stirrer (Ika Labortechnik, 
Staufen, Germany), PCR-machine (Biometra, Goettingen, Germany), pH-meter 
(Inolab, Weilheim, Germany), pipettes (Gilson, Middleton, WI, USA), power supply 
(Amersham Pharmacia, Piscataway, NJ, USA), real-time PCR machine (Lightcycler, 
Roche, Basel, Switzerland or CFX96 Real Time System, BIO-RAD, Hercules, CA, 
USA), vacuum pump (KNF Neuberger, Munzingen, Germany), vortex-Genie2 
(Scientific Industries, Bohemia, NY, USA), water bath (Grant Instruments Ltd., 
Barrington Cambridge, UK). All other devices are mentioned in the methods section. 
5.1.5 Media and soilutions 
ACK buffer 8.29 g NH4Cl 
1 g KHCO3 
37.2 mg Na2EDTA 
H2O ad 1 l 
pH 7.2-7.4 adjusted with 1 N HCl 
sterilized by 0.2 µm filtration 
PBS 150 mM NaCl 
10 mM Na2HPO4 
2 mM KH2PO4 
pH 7.4 adjusted with 5 N NaOH 
PBS-FBS Dulbecco’s PBS without Ca2+/Mg2+ 
2% FBS (v/v) 
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FACS buffer PBS 
2% FBS (v/v) 
0.01% NaN3 (v/v) 
MACS buffer Dulbecco’s PBS without Ca2+/Mg2+ 
0.5% FBS (v/v) 
2 mM EDTA 
50x TAE buffer 242 g Tris 
57.1 ml 100% acetic acid (v/v) 
100 ml 0.5 M EDTA (pH 8.0) 
H2O ad 1 l 
10x Gitocher buffer 670 mM Tris pH 8.8 
166 mM Ammonium sulfate 
65 mM MgCl2 
0.1% Gelatin 
1x Gitocher buffer (amounts per 
sample, 50 µl total) 
5 µl 10x Gitocher buffer 
2.5 µl 10% Triton-X 
0.5 µl β-mercaptoethanol 
3 µl proteinase K (10 mg/ml) 
39 µl H2O 
  
Solutions for Western blotting:  
Lysis buffer (1x) PBS, pH 7.4-8 or  
mammalian lysis buffer (50 mM Tris-HCl, pH 7.5; 
150 mM NaCl) 
1% NP-40 (or Taurocholat, Triton-X100) 
1 mM PMSF 
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2 mM Benzamidine HCl 
Sample buffer (5x) 0.5 M Tris-HCl, pH 6.8 
0.3% Glycerin (99%) 
0.1% SDS 
0.093% DTT (for reducing buffer) 
few grains bromphenol blue 
Running buffer (5x) 150 g (0.4 M) Tris 
750 g (2 M)Glycine 
ddH2O to 5 l 
To use: dilute 1:5, add 5 ml 20% SDS 
Blotting buffer (1x) 10 mM NaHCO3 
3 mM Na2CO3 
20% Methanol 
Washing buffer (1x) 0.05% Tween in PBS (PBST) 
Blocking buffer (1x) 5% Nonfat dried milk in PBS 
Stripping buffer (1x) 7.5 g (100 mM) glycine, pH 2.9 
ddH2O to 1 l 
 
Cell culture media 
All culture media and solutions were purchased from Gibco (Invitrogen, Carlsbad, 
CA, USA) unless otherwise stated. 
 
DC medium RPMI 1640 + glutamine, (PAA, Pasching, Austria) 
 5% FBS (inactivated, v/v) 
 500 mM β-mercaptoethanol 
 100 U/ml penicillin 
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 100 µg/ml streptomycin 
 25 ng/ml GM-CSF 
Freezing medium 90% FBS 
 10% DMSO 
 
5.1.6 Mouse strains 
All mice were bred and maintained in the mouse facility of the Institute for 
Immunology (LMU, Munich, Germany). 
 
CD11c-Cre 
These mice express the Cre recombinase under the CD11c promoter (Caton et al., 
2007) and were provided by Boris Reizis, Columbia University, New York. Mice 
were kept on the B57BL/6 background. 
DC-LMP1/CD40 
The fusion gene LMP1/CD40 was inserted into the rosa26-locus in LMP1/CD40flSTOP 
mice (Hömig-Hölzel et al. 2008). The LMP1/CD40 gene was cloned downstream of a 
loxP-flanked stop cassette. The LMP1/CD40flSTOP mice were provided by Ursula 
Zimber-Strobl, Institute of Clinical Molecular Biology and Tumor Genetics, 
Helmholtz Center Munich. 
When breeding LMP1/CD40flSTOP mice to CD11c-Cre mice, the expression of 
LMP1/CD40 takes place in CD11c+ cells. In the following sections these double 
transgenic mice are referred to as DC-LMP1/CD40. Mice were kept on the B57BL/6 
background. 
Ly5.1 
Ly5.1 mice express the Ly5.1 allele and were kept on the B57BL/6 background. 
OT-I 
CD8 T cells from OT-I mice express the transgenic Vα2/Vβ5 TCR specific for OVA 
(ovalbumin)257–264 in the context of MHC-I H-2Kb (Hogquist et al., 1994). These mice 
were kept on the B57BL/6 background expressing the Ly5.1 allele. 
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5.1.7 Peptides, proteins and oligonucleotides 
The peptide OVA257-264 and was purchased from PolyPeptide Group (Strasbourg, 
France). 
Oligonucleotides were purchased from MWG-Biotech AG (Ebersberg, Germany) and 
are indicated in the relevant context in the methods section. Sequencing reactions 
were carried out by Sequiserve (Vaterstetten, Germany) or MWG-Biotech AG. 
 
5.2 Methods 
5.2.1 Cellular and immunological methods 
5.2.1.1 Adoptive transfer 
This method involves transfer of T cells from a donor mouse into a recipient mouse. T 
cells were isolated from lymph nodes of donor mice using negative selection (MACS, 
see 5.2.1.11). The purity of T cells was determined by flow cytometry (see 4.2.1.5) 
before i.v. transfer into syngenic recipients of the same sex. The congenic markers 
Ly5.1 allowed subsequent detection of transferred T cells in the recipient. 
5.2.1.2 Cell culture 
Culture of dendritic cells 
Addition of the cytokine GM-CSF leads to in vitro differentiation of DCs from bone 
marrow over the course of several days. A modified version of Inaba’s protocol 
(Inaba et al., 1992) was used. Bone marrow cells were depleted of erythrocytes 
(Mouse Erythrocyte Lysing Kit, R&D Systems) and 1x106 cells/ml were cultured in 
DC-medium in a total amount of 10 ml per 100 mm plate at 37°C and 5% CO2. Fresh 
medium was added every 2-3 days. 
5.2.1.3 CFSE staining and in vivo cytotoxicity assay 
Labeling of cells with CFSE (carboxyfluorescein-diacetate-succinimidylester, Life 
Technologies) allows tracking of cells both in vitro and in vivo. CFSE diffuses into 
the cell, where it binds to amino groups of proteins. By cleavage with intracellular 
esterases, CFSE becomes a fluorescent dye. For in vivo cytotoxicity assays, single cell 
suspensions of whole splenocytes were incubated with OVA257-264-peptide (2 ng/ml or 
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2 µg/ml) for 30 min at 37°C. For CFSE labeling, cells were resuspended in 
prewarmed PBS containing 0.1% FBS and 0.1 µM (peptide low cells), 0.5 µM 
(unloaded control cells) or 2.5 µM CFSE (peptide high cells) was added while 
vortexing to ensure homogeneous staining. Cells were incubated for 10 min at 37°C 
and protected from light. The reaction was stopped by adding an equal volume of pure 
FBS. The cells were washed two times with PBS and resuspended in the desired 
amount of PBS. 20x106 OVA257-264-loaded, CFSE-labeled target cells (33% peptide 
low, 33% control, 33% peptide high cells) were injected i.v. and 21 h later killing of 
target cells was analyzed in the spleens by flow cytometry. 
5.2.1.4 Determination of cell numbers 
A Coulter counter Z2 instrument (Beckman Coulter) was used to determine cell 
numbers. Cell count and size is measured by the change of electrical resistance that a 
cell causes by passing through a small whole in an electrode. For analysis 10 µl of 
cell suspension was diluted in 10 ml conductive solution (Isoton II, Beckman Coulter) 
and 2 drops of a lytic reagent (ZAP-OGLOBIN II, Beckman Coulter) were added to 
remove residual erythrocytes. 
5.2.1.5 Flow cytometry - Fluorescence-Activated Cell Sorting (FACS) 
Flow cytometry can detect various characteristics of single cells such as size, 
granularity and molecular marker expression. Cells are stained with fluorochrome-
coupled antibodies against surface or intracellular antigens. Cells in a fluid stream 
pass a laser beam and several detectors. The resulting information is collected and can 
be used for identification of distinct cell populations within a heterogeneous mixture 
of cells.  
An advanced development of classical flow cytometry is cell sorting. On a specialized 
instrument (FACSAria, BD) the cell population of interest can be defined by the user 
and then be collected by electrostatic droplet deflection. 
In a 5 ml reaction tube 50 µl of a single cell suspension (1-5x106 cells) were mixed 
with 50 µl of a 2x concentrated antibody solution at an appropriate dilution 
(antibodies were titrated before use). The tubes were incubated in the dark at 4°C for 
20 min. The cells were then washed with 2-3 ml FACS buffer to remove excess of 
unbound antibodies (300 x g, 4°C). If biotinylated antibodies were used, a second 
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staining step with fluorochrome-conjugated streptavidin followed. For intracellular 
cytokine staining splenocytes (2x106) were stimulated for 4 h in 1 ml with 100 ng/ml 
LPS for DCs, 1 µg/ml ionomycin and 40 ng/ml PMA for T cells in the presence of 2 
µM GolgiStop (BD), which blocks protein secretion. Intracellular staining was 
performed using the Cytofix/Cytoperm kit (BD) according to the manufacturer’s 
protocol.  
Prior to acquisition all samples were filtered (41 µm mesh; Reichelt Chemietechnik, 
Heidelberg, Germany) to remove cell aggregates. Data were aquired on a 
FACSCalibur with two lasers (488 and 633 nm) or on a FACSCanto II instrument 
with three lasers (488, 633 and 405 nm) and analyzed with FlowJo software 
(TreeStar, Ashland, OR, USA). 
5.2.1.6 Harvesting of blood and organs from mice  
Harvesting peripheral blood  
Before blood extraction, mice were placed under an infrared lamp for few minutes to 
generate vasodilatation. Mice were put in a trap and a small cut was made in the tail 
vein with a scalpel blade. In an eppendorf tube 3-5 drops (100-150 µl) of blood were 
collected and mixed with 50 µl heparin-sodium (25000 I.E./5 ml, Ratiopharm, Ulm, 
Germany). 
 
Harvesting organs and preparation of single cell suspensions  
Mice were sacrificed by cervical dislocation, fixed with needles on a styrofoam pad, 
disinfected with 70 % ethanol and cut open. Thymus, lymph nodes and spleen were 
harvested with fine tweezers and kept on ice in RPMI medium. For generation of 
single cell suspensions organs were placed in a petri dish (Ø 5 cm) between two 150 
µm meshes (Reichelt Chemietechnik) and mashed with a 1 ml syringe plunger 
(Omnifix, Braun, Melsungen, Germany). For optimal recovery of dendritic cells (DC) 
organs were treated by enzymatic digestion: injection with a solution containing 
Liberase DL (0.65 Wünsch units/ml) and DNase I (0.2 mg/ml, both from Roche) and 
incubation for 25 min at 37°C, followed by mechanical dispersion using a cell strainer 
(100 µm, BD). 
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For preparation of bone marrow the hind legs were removed. The bones were cleaned 
from muscles, separated into tibia and femur and quickly disinfected with 70% 
ethanol. The terminal parts of the bones were cut open and the bone marrow was 
flushed out with needle and syringe. For large-scale isolation bones were placed in 
medium and carefully fragmented with a mortar and pestle. Bone marrow was 
harvested from the supernatant and filtered through a cell strainer. 
For preparation of lamina propria cell suspensions, colons were removed, opened 
longitudinally, and washed of fecal contents. Intestines were then cut into 0.5 cm 
pieces, transferred into 15 ml conical tubes, and washed once with 10 ml PBS 
containing 0.5 % BSA. The colons were shaken at 200 rpm for 15 min at 37°C in 10 
ml RPMI, supplemented with 5% FBS and containing 5 mM EDTA to remove the 
epithelial layer. This process was repeated once. The remaining tissue was then 
incubated for 10 min at RT in 10 ml RPMI/5% FCS/15mM HEPES followed by 
shaking at 200 rpm for 1 h at 37°C in 3 ml RPMI/5% FCS/15mM HEPES 
supplemented with 0.65 Wünsch units/ml Liberase DL (Roche). After incubation the 
cell suspension was filtered, pelleted and resuspended in ice-cold RPMI/5% FCS/5 
mM EDTA. The incubation with Liberase was repeated once with the remaining 
tissue. 
 
Erythrocyte lysis 
Erythrocytes from peripheral blood were lyzed using Pharm Lyse reagent (BD) 
according to the manufacturer’s instructions. 
Cell pellets from organs were resuspended in 4 ml ACK buffer and left for 5 min at 
RT. 10 ml FACS buffer was then added and the cells were centrifuged (5 min at 4°C, 
300 x g) prior to resuspension in culture medium or FACS buffer. A more gentle 
treatment (Mouse Erythrocyte Lysing Kit, R&D Systems) was used according to the 
manufacturer’s instructions for bone marrow preparations or if cells were used for 
intracellular cytokine staining. 
After erythrocyte lysis cell pellets were resuspended in the desired amount of medium 
or FACS buffer. 
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5.2.1.7 Generation of bone marrow chimeras 
Recipient mice were lethally irradiated with two separate doses at 550 rad using a 
Cesium source (Gammacell 40, AECL, Mississauga, Canada) and supplied with 
neomycin (1.2 g/l, Sigma-Aldrich) containing drinking water for five weeks. 
Chimeras were analyzed 8-10 weeks after bone marrow transfer. For mixed chimeras, 
Ly5.1 mice were irradiated and reconstituted with 50 % Ly5.1 and 50 % Ly5.2 bone 
marrow from DC-LMP1/CD40 mice. 
5.2.1.8 Detection of cytokines via a cytometric bead array system 
25 ml undiluted mouse serum samples were used for the parallel detection of mouse 
IL-6, IL-10, MCP-1, IFN-g, TNF-a, and IL-12p70 in mouse serum. The mouse 
inflammation bead array system (BD) was used according to the manufacturer’s 
instructions and analyzed with a FACSCanto (Becton Dickinson). Data were analyzed 
with the FCAP Array Software (Soft Flow). 
Frozen intestinal or splenic tissue samples were homogenized in PBS containing a 
cocktail of protease inhibitors (Sigma-Aldrich) via a FastPrep-24 (MP Biomedicals) 
homogenizer. After centrifugation at 10,000 x g to pellet debris, concentrations of 
cytokines in supernatants were measured with the cytometric bead array (BD). 
Cytokine levels were normalized to the total protein levels present in each sample, 
which were measured by Qubit fluorometer (Invitrogen). 
5.2.1.9 Ig Isotype ELISAs 
Immunoglobulin isotypes were determined using a commercial ELISA kit 
(SouthernBiotech). 
5.2.1.10 Histology 
Organs were embedded in O.C.T. compound (Sakura Finetek, Zoeterwoude, The 
Netherlands), snap frozen and cut in 5 µm sections on a cryostat instrument (Jung 
Frigocut 2800 E, Leica Microsystems, Wetzlar, Germany). Sections were air-dried for 
at least 1 h, fixed with acetone (-20°C for 10 min) and stained by standard protocol 
with anti-CD4-FITC (clone GK1.5, eBioscience), anti-CD11c-PE (clone N418, 
eBioscience), anti-B220-AF647 (RA3-6B2, eBioscience), anti-MOMA-Bio (MOMA-
1, BMA Biomedicals) and SA-Cy5 (Life Technologies). Analysis was performed on a 
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BX41 microscope equipped with a F-view II camera and cell^F software (all from 
Olympus, Hamburg, Germany). 
For histopathological examination, organs were fixed in 10 % formalin and embedded 
in paraffin or glycolmethacrylate and methylmethacrylate (GMA/MMA) (Hermanns 
et al., 1981). Sections of 3.0 µm (paraffin) or 1.5 µm (glycolmethacrylate and 
methylmethacrylate) thickness were stained with haematoxylin and eosin (HE), and 
with Giemsa. 
For the staining of Langerhans cells, ears were removed close to the head and split 
into dorsal and ventral halves. The latter were put dermal side down floating on 1 ml 
of 0.5 M ammonium thiocyanate in a 12-well plate for 20 min at 37°C. Ear halves 
were placed on a flat surface and the epidermis was carefully removed and floated on 
cold PBS. Epidermal sheets were then placed on labeled glass slides and fixed in 
acetone at RT for 5 min. After fixing, the epidermal sheets were washed with PBS 
and circled with a hydrophobic pen. Afterwards the slides were placed in a humidified 
box and 100 µl blocking solution (0.25% BSA in PBS with 10% mouse serum) was 
added. After 30 min of blocking at RT, the blocking solution was removed and 60 µl 
staining solution (Fc block 1:400, biotinylated IA/IE 1:100 in blocking solution) was 
added and incubated for 30 min at RT. Epidermal sheets were then washed three 
times with PBS and incubated with 60 µl secondary antibody (SA-Cy3 1:400 in 
blocking solution) for 30 min at RT. After staining, sheets were washed three times 
with PBS and embedded in 50-100 µl Fluoromount-G (Southern Biotech) under a 
cover slip. 
For the detection of anti-nuclear antibodies in the serum, the Mosaik Basisprofil 
(Euroimmun, Lübeck, Germany) was used according to the manufacturer’s 
instructions. Sera were diluted 1:20 and the anti-mouse Cy-3 antibody was diluted 
1:400 in PBS-Tween (included in the kit). 
5.2.1.11 Magnetic cell sorting (MACS) 
Magnetic cell sorting (MACS, Miltenyi Biotec) is a technique that allows isolation of 
various cell subpopulations based on their expression of different antigens on the cell 
surface. In general there are two possible methods for cell sorting: labeling the 
population of interest (positive selection) or labeling all other cells (negative 
selection). The MACS principle is based on the use of monoclonal antibodies that are 
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conjugated to superparamagnetic microbeads. After labeling, the cells are applied to a 
column that is placed in a magnetic field of a MACS separator. There are different 
columns for different purposes and for different numbers of cells. Labeled cells (the 
positive fraction) are retained inside the column by the magnetic field, while the 
unlabeled ones (the negative fraction) pass through. The column is washed three times 
with MACS buffer to remove excess unlabeled cells. After removal of the column 
from the magnetic field, the cells retained in column can be eluted. MACS separation 
was applied to purify dendritic cells (CD11c microbeads, positive selection) and 
CD8+ T cells (CD8+ T cell Isolation Kit, negative selection) from cells isolated from 
spleen and lymph nodes. All procedures were performed according to the 
manufacturer’s instructions. 
5.2.1.12 Depletion of gut commensal microflora 
Animals were provided ampicillin sodium salt (1 g/L; Roth), vancomycin 
hydrochloride (500 mg/L; Roth), neomycin sulfate (1 g/L; Roth), and metronidazole 
(1 g/L; Sigma-Aldrich) in drinking water (Rakoff-Nahoum et al., 2004) from week 3 
to 10. 
5.2.2 Molecular biology methods 
5.2.2.1 Agarose gel electrophoresis 
This technique was used to separate DNA fragments according to their length. By 
comparison to a 100 bp or 1 kb ladder (New England Biolabs (NEB), Ipswich, MA, 
USA) the actual size of the fragments was estimated. Before gel loading the DNA 
samples were mixed with gel loading dye (10% glycerol, xylene cyanol FF). 
Separation was carried out by application of constant voltage (80 V) to an 
electrophoresis chamber containing conductive buffer (TAE). Depending on the size 
of the DNA fragment of interest different amounts of agarose were used (0.5-2% 
w/v). DNA was visualized by addition of ethidium bromide to the gel (0.5 µg/ml) and 
subsequent examination under UV light (312 nm, Intas, Goettingen, Germany). 
5.2.2.2 DNA and RNA isolation and purification 
The following kits were used according to the manufacturer’s protocols. During RNA 
isolation residual amounts of DNA were removed by on-column DNase I treatment. 
All kits were purchased from Qiagen (Hilden, Germany): 
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Isolation of genomic DNA DNeasy Blood & Tissue Kit 
 
Isolation of total RNA RNeasy Mini Kit 
RNeasy Micro Kit (for small cell numbers) 
 
Isolation of genomic DNA without DNA precipitation for genotyping PCR: 
2-5 mm tips from mouse tails were incubated in 50 µl of 1x Gitocher buffer for 6 
hours at 55°C followed by 5 min at 95°C. 
5.2.2.3 Measurement of nucleic acid concentration  
Nucleic acid concentrations were determined by UV absorbance measurement at 260 
nm. For this purpose samples were either used undiluted and measured directly with a 
NanoDrop instrument (Thermo Fisher Scientific, Waltham, MA, USA) or diluted in 
plastic cuvettes (Brand, Wertheim, Germany) and measured with a Biophotometer 
(Eppendorf, Hamburg, Germany). The 260/280 ratio is an indicator of nucleic acid 
purity: values between 1.8-2 are desirable, as this means a low amount of protein 
contamination. 
5.2.2.4 Polymerase chain reaction (PCR) 
Using this method, DNA sequences in CD11c-Cre and DC-LMP1/CD40flSTOP mice 
were amplified from a small amount of template tail DNA. For this process specific 
primers that flank the region of interest are used. A cycle of alternating temperatures 
allows DNA denaturation, primer annealing and DNA synthesis. 
 
Primers: 
CD11c-Cre for: ACTTGGCAGCTGTCTCCAAG 
Cre-ORF rev: GCGAACATCTTCAGGTTCTG 
LMP1 for: AGGAGCCCTCCTTGTCCTCTA 
CD40 rev: CTGAGATGCGACTCTCTTTGCCAT 
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Reaction composition: 
1 µl digested tailpiece 
2.5 µl Primer for (10 pmol/µl) 
2.5 µl Primer rev (10 pmol/µl) 
12.5 µl ReddyMix PCR Master Mix (Abgene, Epsom, UK) 
6.5 µl H20 
 
PCR reactions were performed with a T3 Thermocycler (Biometra) using the 
following program: 
CD11c-Cre: 
Step 1:  95°C 5 min 
Step 2:  95°C 30 sec 
Step 3:  63°C 30 sec 
Step 4:  72°C 30 sec  back to step 2 (30 cycles) 
Step 5:  72°C 10 min 
Step 6:  4°C ∞ 
 
LMP1/CD40: 
Step 1:  94°C 5 min 
Step 2:  94°C 45 sec 
Step 3:  55°C 45 sec 
Step 4:  72°C 1 min 15 sec  back to step 2 (31 cycles) 
Step 5:  72°C 10 min 
Step 6:  4°C ∞ 
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5.2.2.5 Quantitative PCR (qPCR) 
Quantitative PCR is used to determine the exact amount of a particular DNA 
sequence within a sample. There are two different methods to detect the amount of 
PCR product in ‘real time’ during the PCR reaction: SYBR green is a fluorescent dye 
that intercalates with any double stranded DNA, whereas TaqMan probes bind 
specific sequences. These probes are oligonucleotides that are labeled with 
fluorescent dyes, which only give a signal when the probe is bound to DNA. The 
cycle number (crossing point, CP) when fluorescence intensity exceeds a certain 
threshold is correlated with the initial amount of the relevant template DNA. 
 
Detection with TaqMan probes 
Equal amounts of RNA were used for cDNA synthesis with the SuperScript III First-
Strand Synthesis SuperMix for qRT-PCR (Invitrogen). The TaqMan assay was 
performed with the LightCycler TaqMan Master Kit (Roche) and the Universal 
ProbeLibrary Set mouse (Roche) according to the manufacturer’s instructions on a 
CFX96 Real Time System (BIO-RAD) using the primers and probes listed in Table 3. 
Expression levels were normalized to Ubiquitin C and relative quantification was 
calculated using the ΔΔCT-method (Fleige et al., 2006). 
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Gene Forward Primer Reverse Primer Probe # 
UBC 5’-GACCAGCAGAGGCTGA TCTT-3’ 
5’-CCTCTGAGGCGAAGG 
ACTAA-3’ 11 
IL-1β 5’-TGTAATGAAAGACGG CACACC-3’ 
5’-TCTTCTTTGGGTATT 
GCTTGG-3’ 78 
IL-4 5’-GAGAGATCATCGGCATT 
TTGA-3’ 
5’-AGCCCTACAGACGAG 
CTCAC-3’ 
2 
IL-6 5’-GAAGGGCACTGCAGG ATAGA-3’ 
5’-TCCCCAGAGTGTGGC 
AGT-3’ 12 
IL-10 5’-CAGAGCCACATGCTC CTAGA-3’ 
5’-GTCCAGCTGGTCCTT 
TGTTT-3’ 41 
IL-12p35 5’-CCAGGTGTCTTAGCCA GTCC-3’ 
5’-GCAGTGCAGGAATAA 
TGTTTCA-3’ 62 
IL-12p40 5’-GCGCAAGAAAGAAAA GATGAA-3’ 
5’-TTGCATTGGACTTCG 
GTAGA-3’ 82 
IL-17A 5’-CAGGGAGAGCTTCATCT 
GTGT-3’ 
5’-GCTGAGCTTTGAGGG 
ATGAT-3’ 74 
IL-17F 5’-CAAGAAATCCTGGTCCT 
TCG-3’ 
5’-GAGCATCTTCTCCAA 
CCTGAA-3’ 45 
IL-21 5’-TCAGCTCCACAAGATGT 
AAAGG-3’ 
5’-GCCTTCTGAAAACAG 
GCAAA-3’ 100 
IL-22 5’-TTTCCTGACCAAACTC 
AGCA-3’ 
5’-TCTGGATGTTCTGGTC 
GTCA-3’ 17 
IL-23p19 5’-ATAGCCCCATGGAGC AACTT-3’ 
5’-GCTGCCACTGCTGAC 
TAGAA-3’ 25 
IFN-γ 5’-GGAGGAACTGGCAAA AGGAT-3’ 
5’-TTCAAGACTTCAAAG 
AGTCTGAGG-3’ 21 
Foxp3 5’-TCAGGAGCCCACCAGT 
ACA-3’ 
5’-TCTGAAGGCAGAGTC 
AGGAGA-3’ 78 
TNF-α 5’-CTGTAGCCCACGTCG TAGC-3’ 
5’-GGTTGTCTTTGAGAT 
CCATGC-3’ 79 
IDO 5’-GGGCTTTGCTCTACCAC ATC-3’ 
5’-AAGGACCCAGGGGCT 
GTAT-3’ 22 
TGF-β 5’-TGGAGCAACATGTGGA ACTC-3’ 
5’-CAGCAGCCGGTTACC 
AAG-3’ 72 
 
Table 5-2: Primers and probes for quantitative TaqMan PCR. 
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5.2.2.6 Western blotting 
Lysates were separated on a SDS-PAGE gel and transferred to a nitrocellulose 
membrane. Signals were visualized with Western Lightning-ECL (PerkinElmer Inc., 
MA, USA). 
5.2.3 Statistical analysis 
P-values were calculated with Student’s t test using PRISM software (GraphPad 
software, La Jolla, CA, USA) and are defined as: ***: P < 0.001, **: P = 0.001 to 
0.01, *: P = 0.01 to 0.05, n.s.: P > 0.05. Error bars represent standard error of the 
mean (SEM). 
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6 Results 
To study the role of constitutive CD40 signaling in DCs, we used mice expressing a 
fusion protein comprising the signaling domain of the human CD40 and the 
transmembrane domain of LMP1 (LMP1/CD40). The mice were generated by 
crossing mice containing a loxP-flanked transcription and translation termination 
sequence (STOP-cassette) upstream of the LMP1/CD40 coding sequence (Homig-
Holzel et al., 2008) with CD11c-Cre transgenic mice expressing Cre recombinase in 
CD11c+ DCs (Caton et al., 2007). When Cre is expressed it excises the STOP-
cassette and the LMP1/CD40 transgene is placed under the control of the ubiquitously 
active rosa26 promoter (Fig. 6-1). Mice carrying one LMP1/CD40 knock-in allele and 
one CD11c-Cre allele will be referred to as DC-LMP1/CD40 mice. As controls, either 
LMP1/CD40flSTOP or CD11c-Cre mice were used. 
 
Figure 6-1: Conditional expression of LMP1/CD40. 
Schematic representation of the rosa26 locus with the knock-in of the loxP-flanked STOP-
cassette and the LMP1/CD40 transgene. After Cre recombinase is specifically expressed in 
CD11c+ cells, the STOP-cassette is excised and the expression of the transgene LMP1/CD40 
takes place under the control of the ubiquitously active rosa26 promoter. 
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6.1 LMP1/CD40 expression in DC of DC-LMP1/CD40 mice 
We first determined whether LMP1/CD40 is expressed in bone marrow derived 
dendritic cells (BM-DCs). For this purpose we generated BM-DCs from CD11c-Cre 
and LMP1/CD40flSTOP control mice and the double transgenic DC-LMP1/CD40 mice. 
Only the double transgenic mice expressed the transgene (Fig. 6-2, A). Furthermore, 
LMP1/CD40 expression was detected in protein lysate of BM-DCs by Western blot 
analysis (Fig. 6-2, B). 
 
 
Figure 6-2: Expression of LMP1/CD40. 
(A) RT-PCR for LMP1/CD40 (Primers: LMP1 forward and CD40 reverse) on RNA isolated 
from bone marrow derived DC from control and DC-LMP1/CD40 mice. As a positive (pos.) 
control, 293-F cells were transfected with a vector containing LMP1/CD40. (B) Detection of 
human CD40 protein by Western blotting of cell lysates from bone marrow derived DC from 
control and DC-LMP1/CD40 mice. As a loading control, β-actin was detected. 
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6.2 Low activation of DC in spleen and lymph nodes 
As it is known that CD40 triggering on DCs leads to up-regulation of activation 
markers (O'Sullivan and Thomas, 2003), we analyzed the phenotype of DCs isolated 
from spleen and skin-draining lymph nodes from DC-LMP1/CD40. The splenic DCs 
showed lower MHC-II expression and no mature phenotype compared to LPS-
activated DCs and control mice (Fig. 6-3, A). As there might be differences in the 
maturation status between DC subsets, we also distinguished between CD8+ and 
CD8- DCs. The splenic DCs contained fewer CD8+ DCs (Fig. 6-3, B). Again, no up-
regulation of CD86 was observed, and only a weak up-regulation of CD80 in both 
subsets. In the skin-draining lymph nodes we observed a reduction of migratory DCs 
(MHC-II++CD11c+) (Fig. 6-3, C). Notably, neither migratory nor resident DCs 
showed strong up-regulation of CD80 and CD86. Only a small shift of CD80 was 
detected. These results indicate that constitutive CD40 signaling in ex vivo DCs does 
not lead to a significant increase in expression of costimulatory molecules. 
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Figure 6-3: Low up-regulation of CD80. 
Single cell suspensions of spleens (SP, A+B) and skin-draining lymph nodes (sLN, C) from 
control mice, control mice injected with 20 µg LPS 16 hours before analysis and DC-
LMP1/CD40 mice were stained for CD11c, MHC-II (I-A/I-E), CD80 and CD86. The results are 
representative of two independent experiments with similar results, n=3. 
 
DCs secrete the pro-inflammatory cytokine IL-12 after CD40 stimulation in vitro 
(Cella et al., 1996), but IL-12 secretion is thought to require additional signals in vivo 
(Schulz et al., 2000). To test if our mice spontaneously secrete IL-12 and if they can 
be triggered to secrete it in the steady state, we stimulated whole splenocytes with or 
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without LPS for 3 hours and analyzed IL-12 production by intracellular cytokine 
staining. Splenic DCs of DC-LMP1/CD40 mice did not secrete IL-12 spontenously 
and were able to produce IL-12 after LPS stimulation with no significant difference to 
control DCs (Fig. 6-4) These results indicate that CD40 stimulation alone is not 
sufficient for the induction of IL-12 production. 
 
 
Figure 6-4: No increase in IL-12 production. 
Single cell suspensions of spleens were stimulated with 100 ng/ml LPS for 3 h in vitro followed by 
staining of CD11c and MHC-II and intracellular cytokine staining for IL-12. Data pooled from 
two independent experiments, n=4. 
 
6.3 OT-I T cell proliferation and killer assays 
To test whether CD40 stimulated DCs are able to induce proliferation of T cells and 
convert them into effector cells or rather would tolerize them, we transferred 5x104 
OT-I T cells expressing the congenic marker Ly5.1 into control and DC-LMP1/CD40 
mice by i.v. injection. After 24 h mice were immunized with 20 µg of the MHC-I Kb-
restricted OVA257-264 peptide and one control group received in addition 50 µg 
agonistic CD40 antibody (anti-CD40). Blood was analyzed by flow cytometry on the 
following days. In mice additionally immunized with anti-CD40, OT-I T cells 
expanded substantially in response to presented antigen, whereas OT-I T cells in DC-
LMP1/CD40 mice did not proliferate to the same extent, but rather resembled the 
control mice that also received only the peptide (Fig. 6-5, A). To test the function of 
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these T cells we performed an in vivo cytotoxicity assay. On day 16, OVA257-264 
peptide-loaded, CFSE-labeled target cells were injected i.v. and 21 h later killing of 
the target cells was analyzed in the spleens by flow cytometry. Target cells with the 
higher amount of peptide (CFSE high) are the first to be killed by cytotoxic T 
lymphocytes (CTLs), whereas the cells loaded with the lower amount (CFSE low) are 
only killed when a higher number of CTLs or CTL with high antigen avidity are 
present. The CFSE intermediate cells are unloaded and serve as control cells. Killing 
of the target cells was observed only in the anti-CD40 antibody treated control (Fig. 
6-5, B). Therefore DCs activated by LMP1/CD40 are not able to induce effector 
functions of CD8+ T cells, but rather convert them into tolerant or anergic cells. 
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Figure 6-5: No T cell expansion and effector function after immunization with OVA-peptide. 
5x104 OT-I T cells (Ly5.1-positiv) were transferred i.v. into control and DC-LMP1/CD40 mice. 
After 24 h mice were immunized with 20 µg OVA257-264 and one group additionally with 50 µg 
anti-CD40 Ab. (A) Expansion of T cells was measured in the blood by flow cytometry. (B) In vivo 
cytotoxicity assay. On day 16, OVA257-264-loaded, CFSE-labeled target cells were injected i.v. and 
21 h later killing of the target cells was analyzed in the spleens by flow cytometry. Data pooled 
from two independent experiments, n=5-7. 
 
6.4 DC-LMP1/CD40 mice develop severe pathology 
6.4.1 Weight loss and reduced survival 
DC-LMP1/CD40 mice were born at the expected Mendelian ratio (data not shown) 
but they appeared smaller in size (Fig. 6-6, picture) and developed wasting disease. 
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Their body weight was reduced by approximately 35% as compared to controls at 8 
weeks of age (Fig. 6-6). We concluded that the weight loss of DC-LMP1/CD40 mice 
could be an indication for an immune disorder and therefore we also monitored the 
survival of the mice. 
 
Figure 6-6: Reduced body weight. 
Left: Body weight of controls (open squares) and DC-LMP1/CD40 (filled squares) between 3 and 
13 weeks of age. n=3-12 per time point. Right: Picture of an 8-wk-old DC-LMP1/CD40 mouse 
and a negative littermate. 
 
50 % of DC-LMP1/CD40 mice died within the first 12 weeks of age and 100 % of the 
mice died within 18 weeks (Fig. 6-7) indicating a severe pathology. 
 
 
Figure 6-7: Reduced survival. 
Kaplan-Meier plot of survival study of controls (thin line; n=8) and DC-LMP1/CD40 mice (thick 
line; n=8), p<0.0001. 
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6.4.2 Splenomegaly and colon shortening 
As the weight loss and the reduced survival of DC-LMP1/CD40 mice were pointing 
to an immune disorder, we macroscopically examined the organs of the mice. 
Analysis of peripheral lymphoid organs of 8-12 week old DC-LMP1/CD40 mice 
showed that the spleen was enlarged and the colon was thickened and shortened (Fig. 
6-8), indicative of intestinal inflammation. These results were detected in every 
mouse that was sacrificed during the study. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-8: Colon shortening and splenomegaly. 
Size of colon and spleen of indicated mice on a metric scale. Pictures are representative of at least 
n=20 mice per group. 
 
6.4.3 Expansion of granulocytes in the spleen and blood 
To determine the possible causes of splenomegaly, we analyzed the different cell 
types in the spleen. The total number of splenocytes was not significantly different 
between DC-LMP1/CD40 and control mice (Fig. 6-9). Also the amount of CD8- DCs, 
macrophages and NK cells was not altered in transgenic mice. DCs, T and B cells 
were significantly reduced. In contrast, granulocyte numbers were significantly 
increased in the DC-LMP1/CD40 mice and seemed to displace DCs, T and B cells. 
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An increase in granulocyte number is generally associated with inflammation 
(Nathan, 2006). 
 
 
Figure 6-9: Expansion of granulocytes in the spleen. 
Cell counts of indicated populations in the spleen of 8–12 week old controls (open bars) or DC-
LMP1/CD40 mice (filled bars). Pooled results are from three independent experiments. n=6. 
 
Next, we wanted to know how granulocytes developed over time in DC-LMP1/CD40 
mice. Therefore mice were bled weekly from week 3 to 8 and blood was analyzed by 
flow cytometry for granulocytes, T, B and NK cells. At week 3, similar proportions of 
all cell types were found in DC-LMP1/CD40 and control mice (Fig. 6-10). The 
increase in granulocytes and the decrease in T, B and NK cell numbers started at 
week 4. After 8 weeks of age, granulocytes were increased more than 3-fold and other 
cell types were reduced to approximately 10% of that observed in wildtype control 
mice. Therefore we concluded that the splenomegaly might be the result of strong 
granulocytic infiltrations. 
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Figure 6-10: Expansion of granulocytes in the blood. 
Mice were bled from week 3 to week 8 and blood was stained for T, B, NK cells and granulocytes 
and analyzed by FACS, n=3-6 per time point. 
 
6.4.4 Infiltrations of granulocytes in the colon 
Having observed colon thickening macroscopically, we next analyzed colon tissue by 
histology. DC-LMP1/CD40 mice displayed colitis with severely thickened colon 
walls, marked hyperplasia of stromal cells and extensive infiltration of granulocytes 
and lymphocytes within the lamina propria, reduction of goblet cells, and focal 
ulceration of the mucosa (Figure 6-11). These results confirmed the macroscopical 
observation of colon thickening and indicated an immunopathological effect in 
transgenic mice. 
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Figure 6-11: Intestinal inflammation. 
(A), (C), (E): Unaltered colon histology of non-transgenic control mice. Arrows indicate mucosal 
goblet cells (E). (B), (D), (F): Histopathology of the colon in DC-LMP1/CD40 mice with 
thickening of the colon wall (B), hyperplasia of stromal cells and infiltration of granulocytes and 
lymphocytes within the lamina propria (asterisks in B and D) and reduction of goblet cells. 
Granulocytic cell infiltration is indicated by arrowheads (F). GMA/MMA sections. HE-staining. 
Bars = 100 µm. Inset in (F): Giemsa-stained GMA/MMA section of the lamina propria with 
stromal cells, plasma cells, eosinophile and neutrophile granulocytes and lymphocytes. Bars = 10 
µm. Histological pictures are representative of n=3 mice per group. 
 
6.4.5 Spleen histology 
Following the finding that we detected strong infiltrations of granulocytes in the colon 
by histology and an expansion of granulocytes in the spleen and blood by flow 
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cytometry, we next examined the composition of important immune cells such as T, B 
cells and DCs in the spleen by performing immunofluorescence microscopy of spleen 
sections. The analysis revealed that B and T cell areas of DC-LMP1/CD40 mice 
appeared smaller in size compared to control mice at 6 weeks of age and were further 
reduced at 12 weeks of age, confirming flow cytometric results showing a reduction 
of B and T cells in the spleen (Fig. 6-12). At 12 weeks of age the T cell areas were 
interspersed with CD11c+ cells and the typical splenic structure was no longer 
observable. We concluded that the immunological disorder induced in DC-
LMP1/CD40 lead to the loss of normal splenic structure probably due to the extensive 
infiltrations of granulocytes. 
 
 
Figure 6-12: Reduction of B and T cell areas after 12 weeks of age. 
Immunofluorescence microscopy of spleen sections from DC-LMP1/CD40 mice. Frozen sections 
from 6 wk and 12 wk old control and DC-LMP1/CD40 mice were immunofluorescently stained 
for CD4+ T cells (FITC), CD11c+ DCs (PE) and B220+ B cells (AF 647). Bars, 200 µm. 
Histological pictures are representative of n=3 mice per group. 
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6.4.6 Langerhans cells 
DCs that are found in the epidermis are called Langerhans cells. To determine 
whether these cells are also affected by CD40 activation, we isolated epithelial layers 
of the ears of DC-LMP1/CD40 and control mice and stained for MHC-II. We 
observed a significant reduction of Langerhans cells in DC-LMP1/CD40 mice (Fig. 6-
13, A+B). This reduction could be a sign of activation of the Langerhans cells. We 
had also observed a reduction of migratory DCs in skin-draining lymph nodes (sLN) 
of DC-LMP1/CD40 mice, possibly meaning that less Langerhans cells had reached 
the sLN (Fig. 6-3). Following the finding that we also found reduced numbers of 
Langerhans cells in the epidermis, this could indicate that the epidermis is already 
seeded with fewer cells maybe due to a reduction of precursors. Another explanation 
would be that LMP1/CD40-Langerhans cells undergo apoptosis more quickly than 
control cells possibly because of their higher activation level. 
 
 
Figure 6-13: Reduced Langerhans cells. 
(A) Epithelial layers of the ears of indicated mice were stained for MHC-II (I-A/I-E) to detect 
Langerhans cells. Bars, 100 µm. Histological pictures are representative of n=3 mice per group. 
(B) Quantification of Langerhans cells in epidermal sheets. The graph shows the mean of four 
fields counted from two mice per group. 
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6.5 Low T cell activation in spleen and lymph nodes 
DCs are very potent T cell activators and as we had found intestinal inflammation in 
the DC-LMP1/CD40 mice, we next analyzed the activation status of T cells in the 
spleen and in the mesenteric lymph nodes. Flow cytometric analysis revealed that 
CD4+ and CD8+ T cells did not show a significant increase in activated cells (CD62- 
CD44+) in the mesenteric lymph nodes. Also in the spleen, we detected a low 
increase in activated T cells, which was not significant (Fig. 6-14, A), although we 
detected some individual outliers that showed strong activation. 
Intestinal inflammation is often associated with high IL-17 expression; therefore we 
tested the potential of CD4+ T cells to secrete this cytokine. Intracellular cytokine 
staining of PMA/ionomycin-restimulated CD4+ T cells showed no significant 
increase of IL-17+ and IL-17+ IFN-γ+ cells in the mesenteric lymph nodes and the 
spleen of DC-LMP1/CD40 mice (Fig. 6-14, B), although we detected a non-
significant tendency of the T cells to produce more IL-17. However, in contrast to 
CD4+ T cells, the production of IFN-γ by CD8+ T cells in the mesenteric lymph 
nodes was significantly increased (Fig. 6-14, B). 
We concluded that T cell activation in lymph nodes and spleen was not consistent and 
could not be detected in every DC-LMP1/CD40 mouse indicating that T cell 
activation found in these organs was probably not induced by LMP1/CD40-
expressing DC present in these organs but by side effects of the advanced disease. 
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Figure 6-14: Weak T cell activation in spleens and lymph nodes. 
(A) Single cell suspensions of spleen (SP) and mesenteric LN (mLN) from control and DC-
LMP1/CD40 mice were stained for CD3, CD4, CD8, CD44 and CD62L. The results are 
representative of two independent experiments, n=3. (B) Intracellular cytokine staining of 
PMA/ionomycin restimulated CD4+ and CD8+ T cells isolated from mesenteric LNs or spleens of 
indicated mice. Data pooled from two independent experiments, n=3-5. 
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6.6 Autoantibodies and elevated IgA and IgM levels in the 
blood 
In order to determine the degree of activation of the humoral immune response in our 
transgenic mice, we measured the concentration of immunoglobulin isotypes in the 
serum. Because of the severe pathology we observed in the DC-LMP1/CD40 mice, 
we additionally determined whether the mice generated autoantibodies. 
We found significantly high levels of IgM and IgA in the serum of DC-LMP1/CD40 
mice (Fig. 6-15, A). IgA plays an important role in mucosal immune responses and 
may be elevated because of the colitis that was detected by histology. 
Next, we tested if these increased antibody levels also contain anti-nuclear antibodies 
(ANA). ANAs are antibodies directed against the cell nucleus that destroy specific 
tissue in the body, and are therefore considered a sign for autoimmunity. By staining 
HEp-2 cells with sera from control and DC-LMP1/CD40 mice, we found a significant 
increase of ANAs in DC-LMP1/CD40 mice (Fig. 6-15, B). ANAs are generally 
capable to contribute to the onset of an autoimmune disease or can be one of the side 
effects of a disease. 
Here we conclude, that elevated levels of ANAs were likely to be a sign of 
autoimmunity and were of the IgM or IgA isotype as these two isotypes were 
significantly elevated in the serum. 
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Figure 6-15: Elevated levels of IgA and IgM and autoantibodies. 
(A) Immunoglobulin isotype concentrations in the serum of control and DC-LMP1/CD40 mice; 
n=8. (B) Anti-nuclear antibodies (ANA) were scored between 0 and 5 by determining the staining 
intensity on HEp-2 cells; bar, 200µm; p=0.0003; n=4. 
 
6.7 Increase of inflammatory cytokines in the serum, spleen 
and colon 
After having detected elevated ANA levels and intestinal infiltrations, we were 
interested in other inflammatory factors such as cytokines. We therefore examined the 
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mice’s sera, spleens and colons for inflammatory cytokines. For this purpose we used 
the BD™ Cytometric Bead Array (CBA), which is a flow cytometry application that 
allows simultaneous quantification of multiple proteins. 
Sera were taken from control and DC-LMP1/CD40 mice and analyzed for six 
different cytokines. We found a significant increase in IFN-γ, TNF-α and IL-6 in 
comparison with the control (Fig. 6-16, A). All three factors are important pro-
inflammatory cytokines and are associated with autoimmune diseases such as 
inflammatory bowel disease. 
In order to determine the cytokine milieu in tissues, we performed CBA on splenic 
and colonic homogenates. Cytokine concentrations were normalized to the total 
protein content of each sample. In the colon of DC-LMP1/CD40 we detected an 
increase in the same three cytokines that were elevated in the serum (Fig. 6-16, B). In 
the spleen, none of the tested cytokine concentrations were altered compared with 
control mice. 
In summary, these results indicate a local inflammation in the colon, concomitant 
with an increase of inflammatory cytokines in the serum. 
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Figure 6-16: Increase of inflammatory cytokines in the serum and colon. 
(A) IFN-γ , TNF-α , MCP-1, IL-6, IL-10 and IL-12p70 serum concentration from 6-12 week old 
control (open bars) and DC-LMP1/CD40 (filled bars) mice, n=22-24. (B) Cytokine concentrations 
in colon and spleen homogenates from 8-12 week old mice were measured by CBA and 
normalized to total protein content for each sample, n=5-10. 
 
6.8 Characterization of colonic DC 
As we had found an increase of inflammatory cytokines in the gut, we decided to 
characterize the colonic DCs more in detail. 
6.8.1 Reduced CD103+ DC 
We stained single cell suspensions of the colons of DC-LMP1/CD40 and control mice 
for common DC markers. A strong reduction of CD103+ DCs of DC-LMP1/CD40 
mice was detected (Fig. 6-17, A). Similar results were obtained in a study in which 
sorted wildtype DCs were stimulated in vitro with anti-CD40, resulting in a genuine 
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down-regulation of CD103 not caused by cell death (Annacker, 2005). In addition, we 
stained CD103- DCs for activation markers and detected an increase in CD70, CD80 
and CD86 compared to control (Fig. 6-17, B). 
These results indicated that DCs in the colon displayed an activated phenotype and 
did not express CD103 due to loss of the marker or loss of the cells. 
 
 
Figure 6-17: Reduction of CD103+ colonic DCs. 
Single cell suspensions of the colon from DC-LMP1/CD40 and control mice were stained for (A) 
CD11c, MHC-II (I-A/I-E), CD103 and (B) for CD70, CD80 and CD86. The results are 
representative of two independent experiments, n=3. 
 
6.8.2 Increase of IL-23 and other cytokines in colonic DC 
Having found up-regulation of activation markers on colonic DCs, we next analyzed 
cytokine production of splenic or colonic DCs in DC-LMP1/CD40 mice, and 
compared this with the respective DCs of control mice. CD11c+ cells were sorted by 
MACS-beads from colons and spleens of DC-LMP1/CD40 and control mice. After 
sorting, RNA was isolated and transcribed into cDNA in order to perform quantitative 
PCR (qPCR) for a selection of cytokines. The most prominent difference in cytokine 
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mRNA expression was found in IL-23, which is composed of the subunits IL-23 p19 
and IL-12 p40. IL-23 p19 mRNA was significantly elevated in colonic DCs of DC-
LMP1/CD40 mice compared to colonic DCs of control mice (Fig. 6-18, upper row). 
IL-23 plays a key role in the intestine (Ahern et al., 2008; Sarra et al., 2010) by 
promoting TH17 cell responses and gut inflammation. It was also found to be elevated 
in colons in a study where anti-CD40 antibody was injected into Rag-deficient mice 
where IBD is induced after antibody injection (Uhlig et al., 2006). In the same study, 
Uhlig et al. detected a decrease in IL-12 p40 and increase in IL-12 p35; the same 
pattern that we observed in DCs of DC-LMP1/CD40 mice (Fig. 6-18, upper row). IL-
12 p40 and IL-12 p35 are the subunits of the cytokine IL-12.  
In addition, mRNA of the pro-inflammatory cytokine IL-1β was significantly 
increased in colonic DCs of DC-LMP1/CD40 mice compared to control mice. IL-6 
mRNA was also elevated, although this did not reach statistical significance. 
We also found an increase in IL-10, TGF-β and IDO mRNA in the colonic DCs of 
DC-LMP1/CD40 mice (Fig. 6-18, middle and lower row). IL-10 is know to play a 
suppressive role in immune responses, nevertheless IL-10 also has 
immunostimulatory properties, and can induce recruitment, cytotoxicity and 
proliferation of CD8+ T cells (Moore et al., 2001). TGF-β is a potent suppressor of 
inflammation in vivo, but may also exhibit some pro-inflammatory effects (Hill and 
Sarvetnick, 2002). An increase of IDO, which is known to have immunosuppressive 
activity, upon CD40 stimulation has previously been shown (Hwu et al., 2000). In 
addition, non-canonical NF-κB signaling in dendritic cells is required for IDO 
induction and immune regulation (Tas et al., 2007). The induction of the non-
canonical NF-κB signaling pathway was also shown in B-cell specific LMP1/CD40 
expression (Homig-Holzel et al., 2008). 
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Figure 6-18: Increase of inflammatory cytokines in colonic DCs. 
Expression of cytokine mRNA in MACS-sorted (CD11c) DCs of control (open bars) and DC-
LMP1/CD40 (filled bars) mice. Data were normalized to Ubiquitin C, n=4-6. 
 
6.8.3 CD103+ DC in the spleen 
Following the finding that CD103+ DCs are missing in the colon of DC-LMP1/CD40 
mice, we analyzed the expression of CD103 on splenic DCs from these mice. As 
already noted, we detected a reduction of CD8+ splenic DCs (Fig. 6-9). 
Approximately 42 % of CD8+ DCs were CD103+ in the control and DC-LMP1/CD40 
mice (Fig. 6-19). Proportion wise, no difference was detected in CD103 expression 
among CD8+ DCs in the spleen. 
These results indicated that the loss of CD103 on DCs was selectively observed in the 
colon. LMP1/CD40 expression was therefore not the only reason that CD103 
expression disappeared in the colon as also splenic DCs expressed LMP1/CD40. Side 
effects of the intestinal inflammation could possibly play a role in the down-
regulation of CD103 in the colon. 
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Figure 6-19: CD103 expression of splenic DCs. 
Single cell suspensions of spleen from control and DC-LMP1/CD40 mice were stained for CD11c, 
MHC-II (IA/IE), CD8 and CD103. Percentages of cells in each gate (mean ± SEM, n=3) are 
indicated. 
 
6.9 Intrinsic DC activation and lack of colonic CD103+ DC 
development 
In order to assess whether the effects we observed in the DC-LMP1/CD40 mice are of 
intrinsic nature, we generated bone marrow (BM)-chimeras. Irradiated B6 mice, 
expressing the congenic marker Ly5.1, were reconstituted with 50% of Ly5.1+ B6 
bone marrow and 50% of control (Ly5.2+) or DC-LMP1/CD40 (Ly5.2+) bone 
marrow. 
After gating on the congenic markers in control and DC-LMP1/CD40 chimeras, we 
gated on DCs (CD11c+MHC-II+) and examined the activation markers CD70 and 
CD80. Only Ly5.2+ DCs, which were derived from BM of DC-LMP1/CD40 mice, 
showed up-regulation of these activation markers (Fig. 6-20, A), suggesting that this 
activation was intrinsic but not acting in “trans”. We next gated on T cells and found 
no difference between CD44 up-regulation of Ly5.1+ and Ly5.2+ T cells within the 
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same group of chimeras (Fig. 6-20, B), indicating that T cells derived from DC-
LMP1/CD40 BM did not show an altered phenotype. 
As we observed an increase of granulocytes in DC-LMP1/CD40 mice, we also stained 
them in the chimeras. In the chimeras composed of DC-LMP1/CD40 and B6 BM, 
both Ly5.1+ and Ly5.2+ granulocytes accumulated, showing that this effect is not 
specific for granulocytes derived from DC-LMP1/CD40 BM (Fig. 6-20, C). 
Granulocytes did not accumulate in the control chimeras (composed of control and B6 
BM). 
In the colon, only the CD103+ DCs derived from DC-LMP1/CD40 BM were lacking 
(Fig. 6-20, D), although also Ly5.1+ CD103+ DCs were reduced in comparison to the 
control chimeras, suggesting that the reduction might be a side effect of the 
pathology. 
Taken together, this experiment showed that DC activation and the reduction of 
CD103 expression was intrinsically induced by LMP1/CD40 expression. Other 
effects including reduction of CD103 expression were side effects of the immune 
pathology because they were also observed in control cells within the DC-
LMP1/CD40 chimeras. 
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Figure 6-20: Intrinsic effects shown in mixed bone marrow chimeras. 
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Irradiated Ly5.1+ B6 mice were reconstituted with 50% Ly5.1+ B6 bone marrow and 50% 
control or DC-LMP1/CD40 (Ly5.2+) bone marrow. Single cell suspensions of spleens were 
stained for Ly5.1, Ly5.2 and (A) CD11c, MHC-II (IA/IE), CD70, CD80 or (B) CD3, CD4, CD8, 
CD44 or (C) Ly6C, CD11b. (D) Single cell suspensions of colons were stained for Ly5.1, Ly5.2, 
CD11c and CD103. The results are representative of two independent experiments, n=5. 
 
6.10  Increased TH17 cytokines in whole colon tissue 
Immune pathologies with involvement of IL-23 are thought to be associated with the 
induction of IL-17 expression (Sarra et al., 2010). We therefore investigated whether 
IL-17 production was induced in the colon. Gene expression was determined in colon 
tissue homogenates of 3 week and 8-11 week old mice by qPCR. 
TH17 cells produce IL-17A, IL-17F, IL-21 and IL-22. All four cytokine mRNAs were 
more highly expressed in older DC-LMP1/CD40 mice than in controls, although only 
IL-17A and IL-21 mRNA were statistically significantly elevated (Fig. 6-21). In 
young mice in which pathology had not yet evolved, IL-17F was the only TH17 cell 
cytokine for which a significant increase was detected. From these findings, we 
concluded that IL-17 expression evolves with pathology, probably due to increase in 
factors that promote IL-17 expression, such as IL-23, IL-6 and TGF-β. 
We also monitored IL-4 and Foxp3 expression. Both are also expressed by CD4+ T 
cells and are associated with TH2 and Treg cell induction, respectively. No difference 
was found in IL-4 expression, neither in young nor in older mice (Fig. 6-21), but 
Foxp3 was found to be up-regulated in colons of older DC-LMP1/CD40 mice 
compared to controls (Fig. 6-21). These results indicated that pathology was not 
associated with TH2 induction and Foxp3 mRNA was induced during pathology 
progress. Treg cells have possibly infiltrated the tissue or were induced by factors 
within the inflamed colon. 
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Figure 6-21: Increase of IL-17-A, IL-21 and Foxp3 mRNA in colons of DC-LMP1/CD40 mice. 
Expression of cytokine mRNA in colon tissue homogenates. Data were normalized to Ubiquitin 
C, n=4-6. 
 
6.11 The DC-LMP1/CD40 phenotype is T/B-cell dependent 
It has been shown that Rag-deficient mice develop colitis upon anti-CD40 antibody 
injection (Uhlig et al., 2006). We wondered if DC-LMP1/CD40 mice would also 
develop pathology independently of T and B cells. We therefore crossed DC-
LMP1/CD40 mice with Rag1-deficient mice and measured their weight once a week. 
The DC-LMP1/CD40-Rag-/- mice gained weight at the same level as control-Rag-/- 
mice did (Fig. 6-22), but did not gain as much weight as control mice, in a manner 
that is normal for Rag-deficient mice. Both groups looked healthy, appeared normal 
in size and did not develop wasting disease. From these results we concluded that the 
development of pathology we observe in these mice is T- and/or B-cell dependent. 
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Figure 6-22: Weight loss is T/B-cell-dependent. 
Body weight of control-Rag-/- (open triangles) and DC-LMP1/CD40-Rag-/- (filled triangles) in 
comparison to control (open squares) and DC-LMP1/CD40 (filled squares) mice between 3 and 
16 weeks of age. n=2-6 per time point. 
 
6.12  The DC-LMP1/CD40 phenotype is dependent on 
commensal bacteria 
We found strong DC activation in DC-LMP1/CD40 mice in the colon. Therefore, we 
speculated that commensal bacteria might be an additional trigger for the CD40-
activated DCs to induce up-regulation of activation markers and cytokine production. 
To investigate this, we added four different antibiotics to the mice’s drinking water 
starting at the age of three weeks onwards in order to deplete commensal bacteria. As 
DC-LMP1/CD40 mice looked healthy and gained weight to the same extent as control 
mice, we stopped the treatment at week 10 to determine if the effect is reversible. 
Then they started to loose weight immediately (Fig. 6-23) but still looked healthy for 
approximately 10 weeks, after which they began to assume a hunched posture and 
scrubby fur and lost weight more rapidly, necessitating sacrifice at week 28. These 
experiments indicate that the development of pathology is strictly dependent on 
commensal bacteria. 
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Figure 6-23: DC-LMP1/CD40 phenotype is dependent on commensal bacteria. 
Mice were treated with antibiotics for commensal bacteria depletion from week 3 to 10. Body 
weight of antibiotics-treated control (open circles) and DC-LMP1/CD40 (filled circles) mice in 
comparison with untreated DC-LMP1/CD40 (filled squares) mice between 4 and 28 weeks of age. 
n=2-6 per time point. 
 
6.13 BM-DC stimulation 
We found an important role of commensal bacteria in the onset of pathology. These 
additional triggers derived from bacteria might be TLR signals. We therefore tested 
how sensitive LMP1/CD40-DCs respond to TLR stimulation. For this purpose we 
used Lipopolysaccharide (LPS), which binds to TLR4. We stimulated BM-DCs from 
control and DC-LMP1/CD40 mice with 0.4 ng/ml LPS for 3 h and stained for CD11c, 
MHC-II, CD70 and CD80 expression before and after stimulation. The ratio of 
stimulated and unstimulated cells was calculated by the division of the percentage of 
markerhigh stimulated cells by the percentage of markerhigh unstimulated cells. 
We found that unstimulated BM-DCs of DC-LMP1/CD40 mice contained fewer 
MHC-IIhigh, fewer CD70high and fewer CD80high DCs than the BM-DCs of control 
mice (Fig. 6-24, upper part). After 3 h of LPS stimulation, BM-DCs of LMP1/CD40 
mice did not express higher amounts of the activation markers than the control DCs 
(Fig. 6-24, middle part). However, when calculating the ratio of markerhigh cells of 
stimulated cells and the markerhigh cells of unstimulated cells, we detected a 
significantly greater increase in DC-LMP1/CD40 BM-DCs, suggesting that DCs were 
more sensitive to LPS stimulation despite their lower activation level (Fig. 6-24, 
lower part). From these results we conclude that constitutive CD40 signaling in DCs 
converts them into more sensitive DCs that respond to LPS more strongly. 
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Figure 6-24: Higher sensitivity of DCs for LPS stimulation. 
BM-DCs of control and DC-LMP1/CD40 mice were stimulated with 0.4 ng/ml LPS for 3 h and 
stained for CD11c, MHC-II, CD70 and CD80 expression (A) before and (B) after stimulation. (C) 
The ratio was calculated by the division of markerhigh stimulated cells (%) by markerhigh 
unstimulated cells (%). The results are representative of one experiment, n=3. 
 
In summary, CD40-activated DCs do not fully mature, confirming previous data 
(Schulz et al., 2000), and instead achieve an activation level at which they become 
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very sensitive to additional triggers, like such that are present in the intestine. They 
are no longer able to induce tolerance locally, which is normally a very important 
feature of DCs in the gut. However, CD40-activated DCs in the spleen did not 
produce pro-inflammatory cytokines and did not induce T cell proliferation and 
effector function. 
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7 Discussion 
The tolerogenic phenotype of DCs remains a topic of debate; in order to influence the 
maturation state of DCs we expressed a constitutively active CD40 molecule under 
the CD11c promoter. These DC-LMP1/CD40 mice developed colitis, wasting disease, 
splenomegaly, increased levels of serum pro-inflammatory cytokines and increased 
levels of serum IgA and IgM. Fully matured DCs were detected in the intestines but 
not in the spleens of these mice, suggesting that additional triggers in the gut may lead 
to complete maturation of the DCs and be the cause of intestinal pathology. However, 
tolerance was induced in transfer experiments where OT-I T cells were administered 
systemically. We therefore only found a local activation of DCs accompanied by loss 
of tolerance. 
 
7.1 Generation of DC-LMP1/CD40 mice 
Experiments studying CD40 stimulation of DCs in vivo are typically conducted using 
an agonistic anti-CD40 antibody. However, as already mentioned, the problem with 
this approach is that also B cells and macrophages are also triggered by this 
stimulation and that a necroinflammatory liver disease can be induced (Kimura et al., 
2006). In vitro studies with CD40 ligation on DCs are also problematic because of 
reasons already discussed in the introduction (see section 3.3.1). In addition, it has 
been shown that DCs show different activation marker kinetics whether anti-CD40 
antibody is given in vivo or in vitro (Frleta et al., 2003). Our DC-LMP1/CD40 
transgenic mouse expresses LMP1/CD40 under the CD11c promoter and thus 
transmits the chronic CD40 signal primarily to DCs. This DC-restriction is likely to 
not be complete due to the behaviour of the CD11c promoter; when CD11c-Cre mice 
were crossed to a EYFP-reporter, EYFP expression was observed in > 95% of splenic 
DCs, compared with < 10% of lymphocytes and < 1% of myeloid cells such as 
granulocytes (Caton et al., 2007). Thus it is possible that there is a minor background 
expression of LMP1/CD40 on other cell types than DCs in our mice, which must be 
considered. In mixed BM-chimeras we did not detect differences in activation of T 
cells or in proliferation of granulocytes, suggesting that possible unspecific expression 
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of LMP1/CD40 expression in cell types other than DCs did not play a role in our 
system. 
By RT-PCR and Western analysis we showed that the STOP-cassette was 
successfully deleted in BM-DCs of DC-LMP1/CD40 mice and RNA and protein of 
LMP1/CD40 was detected, respectively. In DC-LMP1/CD40flSTOP mice in which the 
STOP-cassette is still present, we did not see any transcripts or protein of 
LMP1/CD40, demonstrating that transcription does only take place when Cre 
recombinase is expressed. 
 
7.2 Impaired T cell activation, expansion and effector 
function in the periphery 
We did not detect a significant up-regulation of costimulatory molecules on DCs in 
the spleen and the skin-draining lymph nodes of DC-LMP1/CD40 mice; only CD80 
was increased to a small extent. It has been previously observed that in vivo CD40 
stimulation of DCs via anti-CD40 antibody resulted in a 2-3-fold increase in CD80 
and CD86 expression, but this was not sustained over 5 days (Frleta et al., 2003). In 
fact, we even observed down-regulation of MHC-II in the DC-LMP1/CD40 mice, 
which corresponds to similar observations upon application of an anti-CD40 antibody 
in vivo (Frleta et al., 2003). Frleta et al. suggested that the down-regulation of MHC-II 
may be a means to select for high affinity CD4+ T cells by limiting the pool of MHC-
II complexes, as this phenomenon has previously been reported for CTLs and MHC-I 
complexes (Kedl et al., 2002). 
When we transferred OT-I T cells into DC-LMP1/CD40 mice, the CD40 stimulus via 
LMP1/CD40 on DCs and the resulting DC activation was not sufficient to induce 
substantial proliferation and effector functions of these cells. In the positive control 
group of wildtype mice injected with an agonistic anti-CD40 antibody, OT-I T cells 
expanded to a greater extent and developed effector functions. However, the use of 
the anti-CD40 antibody activates B cells and macrophages as well as DCs, and 
therefore a combination of secreted factors by different cell types may be the reason 
for the strong T cell proliferation and killing capacity. 
Endogenous T cells in the spleen and mesenteric lymph nodes of DC-LMP1/CD40 
mice did not show significant activation in our mice, indicating that DCs in the 
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periphery were not fully matured. Only CD8+ T cells in the mesenteric lymph node 
secreted higher amounts of IFN-γ. In the mesenteric lymph nodes, predominantly 
CD103- DCs, derived from the lamina propria, induce IFN-γ production by CD8+ T 
cells, which suggests that activated DCs had reached the mesenteric lymph nodes in 
the DC-LMP1/CD40 mice. 
 
7.3 Inflammatory cytokines in DC-LMP1/CD40 mice 
In the serum of DC-LMP1/CD40 mice, we found a significant increase of IFN-γ, 
TNF-α and IL-6, indicating inflammation. However, when we measured whole colon 
and whole splenic tissue cytokines, we found elevated levels of serum cytokines and 
MCP-1 only in the colon. MCP-1 is mainly secreted by monocytes, macrophages and 
dendritic cells and attracts memory T cells, monocytes and dendritic cells to sites of 
inflammation. These findings, together with the microscopic observations of the 
intestinal infiltrations, indicated that a local inflammation in the colon of DC-
LMP1/CD40 mice was induced. 
In the colon, but not in the spleen, we demonstrated that DCs expressed high amounts 
of the pro-inflammatory cytokines IL-23, IL-12 and IL-1β. IL-6 was also elevated. 
We also showed an increase of TH17 cytokines in whole colon tissue, which could be 
the result of TH17-inducing cytokines, such as TGF-β, IL-6 and IL-23, secreted by 
colonic DCs. We cannot exclude that IL-17 is also produced by cell types other than 
TH17 cells, because it has been shown that there can be also T-cell independent IL-17 
production in the gut (Uhlig et al., 2006). In support of this, it has been demonstrated 
that CD40 plays a pivotal role in TH17 induction, and that it acts to trigger IL-6 
release from DC in the context of bacterial infection (Perona-Wright et al., 2009). It 
has also been shown that TH17 cells are associated with autoimmune disorders 
(Hemdan et al., 2010) and promote granulopoiesis (Smith et al., 2007). 
In fact, we detected massive infiltrations of granulocytes in the colon of DC-
LMP1/CD40 mice and an increase of granulocytes in the blood over time. We also 
observed an expanded granulocyte population in the spleen. 
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However, not only inflammatory, but also immunosuppressive cytokines were 
expressed in DC-LMP1/CD40 mice. IDO exerts an immunosuppressive role. The 
expression of IDO by DCs was shown to be induced by IFN-γ and CD40 ligation 
(Hwu et al., 2000). In DC-LMP1/CD40 mice, IFN-γ was present in high amounts in 
the colon and IDO expression was detected in DCs. Presumably, production of IDO 
by activated DCs contributes to a mechanism to self-limit immune responses (Hwu et 
al., 2000). A similar regulatory role might be possible for IL-10. It has been shown 
that IL-10 is secreted by DCs upon microbial stimuli and CD40 (Edwards et al., 
2002). In the context of DC-LMP1/CD40 mice IL-10 was induced in colonic DCs, 
suggesting that CD40 stimulated colonic DCs tried to self-limit immune responses. 
 
7.4 Role of CD103+ DCs in the gut 
In the steady state, colonic DCs constantly migrate to the mesenteric LN (mLN), 
where they present antigens, such as those sampled from commensal bacteria 
(Macpherson and Uhr, 2004) and apoptotic epithelial cells (Huang et al., 2000), to T 
cells for tolerance induction. The CD103+ DCs are mainly migrating to the mLN and 
play an important role for induction of tolerance. In mice in which constitutive DC 
trafficking to the mLN is impaired because of CCR7 deficiency, induction of 
tolerance to oral antigens is defective (Worbs et al., 2006). Intestinal CD103+ DCs 
can induce expression of the chemokine receptor CCR9 and α4β7 integrin, both 
known as gut-homing receptors. CD103+ DCs also contribute to control 
inflammatory responses and intestinal homeostasis by inducing Foxp3+ Treg cells 
(del Rio et al., 2010; Ng et al., 2010). As CD103+ DCs are strongly reduced in the 
colon of DC-LMP1/CD40 mice, it is possible that this deficiency may contribute to 
loss of tolerance. However, it has been shown that, upon CD40 ligation, CD103 is 
down-regulated on DCs (Annacker, 2005) and we do not know whether DCs with 
characteristics of CD103+ DCs may still reside within the CD103- population. The 
down-regulation of CD103 by CD40 ligation might by a mechanism for CD40L+ T 
cells to overcome suppression by Treg cells. Nevertheless, we detected Foxp3 
expression in whole colon homogenates of 3 and 8-11 week old mice. In support of 
this, Treg cells are found in normal numbers in Batf3-/- mice that lack intestinal 
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CD103+CD11b- DCs (Edelson et al., 2010). The results suggested that CD103 
expression by DCs was dispensable for the presence of Foxp3 expressing cells. 
In mixed bone marrow chimeras we showed a reduction of colonic CD103+ DCs 
derived from DC-LMP1/CD40 BM in comparison to wildtype DCs present in the 
same mouse, allowing us to assume that the reduction of CD103+ DCs in the 
transgenic mice is an intrinsic effect that is not mediated in trans. To our surprise, the 
CD103+ wildtype DCs within the DC-LMP1/CD40 chimeras were reduced in 
comparison to the CD103+ DC in the control chimeras, possibly due to the onset of 
disease. It is possible that activated CD40L+ T cells in the gut may interact with the 
CD103+ wildtype DCs and induce CD103 down-regulation, as speculated above. 
However, further experiments are needed to clarify the mechanism by which CD103 
was down-regulated in DC-LMP1/CD40 mice. 
 
7.5 Constitutive CD40 signaling in DCs does not induce 
immune pathology without microbial stimulation 
In view of the fact that we detected local inflammation in the gut, we investigated the 
outcome of depleting commensal bacteria in DC-LMP1/CD40 mice by antibiotic 
treatment in the drinking water. Although we did not test the depletion efficacy, the 
protocol we used for commensal-depletion has been employed previously (Rakoff-
Nahoum et al., 2004; Xiao et al., 2007) and was shown to reduce commensal bacteria 
to a non-detectable level (Rakoff-Nahoum et al., 2004). Unlike their non-treated 
transgenic littermates, the antibiotic-treated DC-LMP1/CD40-mice were healthy and 
did not loose weight until the end of treatment. This finding suggests that gut DCs of 
DC-LMP1/CD40 mice with intact gut flora are no longer able to maintain tolerance 
due to bacterial recognition. In wildtype mice, intestinal DCs engulf commensal 
bacteria and present them to T cells in a tolerance-inducing manner (Iwasaki, 2007; 
Rescigno et al., 2001). The CD40 signal may convert DCs into a semi-mature state in 
which they cannot tolerate additional triggers and start to produce pro-inflammatory 
cytokines. These data confirm studies showing that DCs can only fully mature when a 
microbial trigger is added to CD40 ligation (Schulz et al., 2000). 
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7.6 Development of disease is T and B cell dependent 
In order to investigate if the onset of disease in DC-LMP1/CD40 depends on T and B 
cells, we crossed the mice to Rag-/- mice, which lack mature T and B cells. 
Interestingly, as already mentioned, it has been shown that injection of an agonistic 
CD40 mAb to T and B cell deficient mice was sufficient to induce a pathogenic innate 
inflammatory response systemically and in the intestine that was functionally 
dependent on TNF-α, IFN-γ, IL-12p40 and IL-23p40 (Uhlig et al., 2006). 
Considering these results, we expected the DC-LMP1/CD40-Rag-/- mice to develop 
colitis. Surprisingly, they developed normally and were disease free. The difference 
between the two systems is that, upon anti-CD40 antibody injection into Rag-/- mice, 
the antibody also binds other cells than DCs, such as monocytes, activated 
macrophages, endothelial and epithelial cells (Diehl et al., 2000). In the DC-
LMP1/CD40 mice, only the DCs were activated via CD40. In the case of the antibody 
study, non-DC cell types may produce inflammatory cytokines that lead to 
inflammation. In contrast, in DC-LMP1/CD40 mice activated DCs can act only via T 
cells for disease development, which in turn secrete inflammatory mediators like IFN-
γ and IL-17. 
 
7.7 Increased sensitivity for microbial molecular patterns of 
CD40 stimulated DCs 
In order to test how DCs of DC-LMP1/CD40 mice up-regulate costimulatory 
molecules in response to a TLR ligand, we stimulated BM-DCs with LPS. Intestinal 
DCs typically encounter TLR stimuli as they sample bacteria through the intestinal 
epithelium. We found that LMP1/CD40-DCs up-regulated MHC-II, CD70 and CD80 
stronger than control DCs in response to LPS, indicating that LMP1/CD40-DCs 
exhibited a lower maturation threshold. This higher increase of costimulatory 
molecules might be an indicator of an enhanced sensitivity to TLR triggering that may 
explain why DCs in the gut of DC-LMP1/CD40 are not able to stay immature or 
semi-mature but rather become fully matured, immunogenic DCs. 
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7.8 Conclusion 
In this study we wanted to address the question of how important regulation of DC 
activation is and whether other maturation states, in addition to immature and mature 
DCs, exist which can have an impact on tolerance induction. For this purpose we 
generated transgenic mice with a DC-specific constitutive CD40 signal. 
From our results, we conclude that CD40-triggering of DCs in vivo, in absence of 
additional activators such as bacterial TLR-ligands derived from the gut, do not 
secrete critical levels of pro-inflammatory cytokines and are not immunogenic. 
However, LMP1/CD40-DCs in the gut secrete high amounts of IL-23, IL-6, IL-12 and 
IL-1β, inducing expression of IFN-γ and IL-17, probably due to TH17 and TH1 
activation. In this cytokine milieu, granulocytes infiltrate the colon causing tissue 
damage that results in colitis (Fig. 7-1). 
We showed that the constitutive CD40 signal lowers the activation threshold of DCs, 
which does not result in any harmful impact on most organs. Only additional stimuli 
at borders of the body, such as the gut and the skin, strongly activate DCs, inducing 
DC migration and triggering inflammatory autoreactive immune responses. In the 
skin we did not find any pathological consequences such as psoriasis. The behaviour 
of these DCs in the lung, which represents another body border, remains to be 
investigated. 
Thus, we show for the first time that CD40 crosslinking is an important mediator for 
the amplification of other DC activation signals, such as microbial stimuli in vivo. As 
a consequence, otherwise tolerating DCs become immunogenic, causing 
autoimmunity. These findings demonstrate that DC maturation must be tightly 
regulated in order to avoid autoimmune disorders. 
 
DISCUSSION 
 76 
 
Figure 7-1: Dysregulation of intestinal immune homeostasis in DC-LMP1/CD40 mice. 
During homeostasis the intestine holds a balance between pro-inflammatory cytokines from 
innate (e.g., IL1β , IL-6, IL-12, IL-23) and effector T cell populations (e.g., TH1 and TH17 cells), 
relative to regulatory T cell populations that are influenced by factors such as IL-10, TGF-β  and 
retinoic acid (RA) in the environment. In DC-LMP1/CD40 mice there is dysregulation of this 
balance, with an increased proportion of granulocytes and IL-17-producting cells. Modified from 
(Abraham and Cho, 2009). 
 
7.9 Outlook 
Dendritic cells play a crucial role in priming adaptive immune responses and in the 
induction of self-tolerance. The general understanding is that immature DCs induce 
tolerance and mature DCs induce immunity. Furthermore, it has been suggested that 
there might be also mature DCs with tolerogenic potential (Reis e Sousa, 2006). Our 
study aimed to further the understanding of DC maturation and tolerance induction. 
The presented work highlights the importance of tight regulation of DC maturation. 
CD40-activated colonic DCs have a lower activation threshold and are therefore more 
sensitive to TLR stimulation. Further work is needed to identify the precise 
mechanism by which CD40-stimulated colonic DC induce pathology and down-
regulate CD103. In addition, the induction of Treg cells in the gut is of great interest, 
as it has been claimed that Treg cell induction is dependent on CD103+ DCs 
(Siddiqui and Powrie, 2008), and CD103 expression is lacking in the colon of DC-
LMP1/CD40 mice, although Foxp3 expression is still detected. 
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These findings may contribute to a better understanding of DC involvement in 
tolerance induction and therefore translate into more precise therapeutic control over 
autoimmune diseases. Furthermore, DC vaccination is a promising immunological 
approach against tumors, although only limited success has so far been achieved with 
this methodology. An enhanced understanding of DC maturation mechanisms is 
crucial for improving such potential therapies. 
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